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ABSTRACT
The current research project was developed in two lines within the main framework
of the application of computational chemistry approaches on studies of biological systems.
The first line, carried in the group of Theoretical Chemistry of the University of Porto, is
related to the area of drug design and includes two parts of the project. The first part
aimed at providing insights for the design of novel drugs for treatment of hypertension.
Here, the model of the target angiotensin II receptor type 1 (AT1) receptor, which is
involved in the renin-angiotensin-aldosterone-system (RAAS) cascade, was modelled by
homology modelling approach. The binding poses of the natural substrate Angiotensin II,
peptide hormone that causes vasoconstriction, to the created model of the target were
identified by molecular docking study. The molecular docking protocol was also employed
to dock several AT1 antagonists to the modelled target. The second part aimed to perform
preparation of the enzyme macrocyclase PatG (PatGmac) system for the study of its
catalytic mechanism. The system was created on the base of X-ray structure and fully
optimised by the hybrid QM/MM ONIOM method. In future, it would be useful for
production of potential anticancer molecules "patellamides”, linear peptides cyclised by
this enzyme.
The second line of the project, carried in the group of Theory of Condensed Matter
of the University of Groningen, is related to the study of protein conformational changes
by means of two-dimensional infrared spectroscopy (2DIR). Theoretical methods capable
of detailed simulation of two-dimensional spectra of full proteins from molecular dynamics
trajectories have been applied for the proteins to test the method on big biological
systems.
Key words: Drug Design, hypertension, RAAS, AT1 receptor, angiotensin II,
AT1 antagonists, homology modelling, molecular docking, PatGmac, patellamides,
ONIOM QM/MM, 2DIR spectroscopy, Molecular Dynamics
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RESUMO
O presente projeto de investigação foi desenvolvido em duas linhas, tendo por
base abordagens de química teórica e computacional em estudos de sistemas
biológicos. A primeira componente, realizada no grupo de Química Teórica da
Universidade do Porto, está relacionada com um estudo de desenho de fármacos e
divide-se em duas partes deste projeto. Na primeira parte pretendeu-se a aquisição de
conhecimentos para a concepção de novos fármacos para o tratamento da hipertensão.
Inicialmente modelou-se o receptor transmembranar da angiotensina II, subtipo 1 (AT1), o
qual está envolvido na cascata sistema-renina-angiotensina-aldosterona (RAAS),
utilizando o método de modelação por homologia. Utilizou-se o método de atracagem
molecular para se identificaram as diferentes conformações de ligação do substrato
natural angiotensina II, hormona peptídica que provoca vasoconstrição, ao modelo do
receptor AT1 criado por modelação por homologia. O mesmo protocolo de atracagem
molecular foi posteriormente utilizado para atracar vários antagonistas do receptor AT1
(comercialmente utilizados) ao alvo modelado.
Na segunda parte realizou-se a preparação do sistema da enzima macrociclase
PatG (PatGmac) para o futuro estudo do seu mecanismo catalítico. O sistema foi criado a
partir da estrutura de cristalografia de raio-X, e de seguida foi optimizado pelo método
híbrido QM/MM ONIOM. Este procedimento é necessário para o estudo do mecanismo
catalítico, o qual será muito útil para a produção de moléculas "patelamidas", péptidos
cíclicos produzidos por esta enzima, que actuem como potenciais fármacos anti-
cancerígenos.
A segunda linha do projeto, realizado no grupo de Teoria da Matéria Condensada
da Universidade de Groningen, está relacionada com o estudo de mudanças
conformacionais de proteínas por meio de espectroscopia de infravermelho bidimensional
(2DIR). Foram aplicados métodos teóricos capazes de simular detalhadamente os
espectros bidimensionais de proteínas completas através trajectórias de dinâmica
molecular. O método foi testado em proteínas pertencentes a grandes sistemas
biológicos.
Palavras-chave: Desenho de fármacos, Hipertensão, RAAS, Receptor AT1,
Angiotensina II, Antagonistas do AT1, Modelação por Homologia, Atracagem Molecular,
PatGmac, Patelamidas, ONIOM QM/MM, 2DIR Espectroscopia, Dinâmica Molecular
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I. INSIGHTS FOR THE DESIGN OF NOVEL
DRUGS FOR HYPERTENSION
1. INTRODUCTION
Hypertension, or high blood pressure, is a chronic condition recognized as one of
the leading causes for human morbidity and mortality worldwide through its effects on
target organs like heart, brain and kidneys. It is a major risk factor for myocardial
infarction, congestive heart failure, stroke, and end-stage renal disease all of which
convey risk of significant morbidity and mortality [1].
Despite the huge problem of the disease and the existence of several different
classes of antihypertensive pharmacological drugs, the incidence of hypertension and
related cardiovascular diseases remains steadily on the rise, and relatively few patients
achieve the targeted blood pressure level. Moreover, majority of available
pharmacological agents for hypertension present severe side effects to the organism.
The renin-angiotensin-aldosterone system (RAAS) plays an important role not only
in the control of blood pressure, but in the pathogenesis of diabetes and kidney diseases.
While it has been difficult to demonstrate in vivo activation of the RAAS in early or
established hypertension in humans, there is no doubt that inhibition of the RAAS is
effective in lowering blood pressure in patients with primary hypertension. The results of
multiple clinical trials demonstrate that blocking the RAAS through the targets of
angiotensin-converting enzyme (ACE) or angiotensin II receptor type 1 (AT1), which are
parts of the proteolytic cascade of the RAAS, with the corresponding inhibitors not only
lower blood pressure, but also reduces cardiovascular events and total morbidity and
mortality [1, 2]. Thus, it makes the study of this system highly important, and design of
new blocking agents to this cascade is an attractive therapeutic strategy.
The aim of the project was to provide insights for the design of novel drugs for
hypertension involving theoretical and computational calculations. The study has been
performed focusing on creating a model of the AT1 receptor, identifying the binding poses
of Angiotensin II and several AT1 antagonists. Homology modelling, force-field
minimization, and molecular docking calculations were used during the study.
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2. RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM (RAAS) IN
HYPERTENSION
2.1 GPCR receptors
G protein-coupled receptors (or GPCRs), also known as seven-transmembrane
domain receptors (7TM receptors), are integral membrane proteins that contain seven
membrane-spanning helices. As the name suggests they are coupled to heterotrimeric
G proteins on the intracellular side of the membrane. Upon ligand binding, the GPCR
undergoes a conformational change that is transmitted to the G protein causing activation.
Further signal transduction depends on the type of G protein.
GPCRs are the largest and most diverse group of membrane receptors in
eukaryotes. They are activated by a wide variety of ligands, olfactory stimulants, peptides,
hormones, neurotransmitters and light. They are grouped into 6 classes based on
sequence homology and functional similarity:
Class A (or 1) (Rhodopsin-like);
Class B (or 2) (Secretin receptor family);
Class C (or 3) (Metabotropic glutamate/pheromone);
Class D (or 4) (Fungal mating pheromone receptors);
Class E (or 5) (Cyclic AMP receptors);
Class F (or 6) (Frizzled/Smoothened).
GPCRs are the target of around half of all modern medicinal drugs. Their
expression on the cell surface makes them readily accessible to hydrophilic drugs and
their non-uniform expression provides selectivity in activating or blocking physiological
events. Agonists and antagonists of GPCRs are used in the treatment of disease in every
organ system.
GPCRs are the targets of almost 50% of all drugs currently available on the
market [3]. Class A GPCRs (or Rhodopsin-like) share the same basic topology of seven
transmembrane helices connected by three extracellular and three intracellular loops. The
receptor is capped with an extracellular amino terminus and intracellular carboxyl
terminus (Fig. 1).
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Fig. 1 – Schematic representation of the class A GPCR topology. This picture shows an “activated” GPCR
embedded in a lipid bilayer. The C-terminus of the receptor is associating with the G-protein trimer.
2.2. AT1 receptor
The angiotensin II type I (AT1) receptor is a class A GPCR (Fig. 1) and is involved
in the RAAS (Fig. 2).
Fig. 2 – A diagram illustrating the RAAS cascade, beginning with angiotensinogen and ending with the binding of
angiotensin-II to the AT1 receptor.
The RAAS plays a key role in blood pressure regulation and electrolyte
homeostasis, and it is involved in the pathogenesis of hypertension and renal diseases.
The RAAS system is a proteolytic cascade that starts with the release of the enzyme renin
by the juxtaglomerular cells located in the kidney. Renin binds a plasma protein named
angiotensinogen (452 amino acids) and hydrolyses the peptidic bond between the 10th
and 11th positions, releasing a decapeptide known as angiotensin I (Ang-I). Ang-I remains
biologically inactive until it is further cleaved into the octapeptide angiotensin II (Ang-II) by
the metalloprotease angiotensin-converting enzyme (ACE) [4]. Ang-II is the main effector
The renin-angiotensin-aldosterone system (RAAS)
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hormone of the RAAS. Ang-II subsequently binds and activates a transmembrane
receptor AT1 located in the cardiovascular, neuronal, endocrine and hepatic cells [5].
AT1 activation – the last binding of Ang-II to AT1 receptor – induces cardiovascular events
such as vasoconstriction, inflammatory response, aldosterone release and salt
retention [6, 7]. Many antagonists have been designed to block this interaction in order to
treat clinical cases of hypertension [8].
The AT1 receptor, a 359-aminoacid protein, is widespread in organs and tissues,
but is found predominately in vascular and myocardial tissue, the liver, the adrenal cortex
and some areas of the brain [9, 10]. The design and development of AT1 blockers could
be useful as specific remedies for many pathologies like hypertension, heart and kidney
failures. Therefore, a knowledge of the 3D structure of the AT1 receptor could be of great
help in this task.
The 3D-structure of a protein is usually obtained experimentally and the main
techniques for this purpose are X-ray crystallography and Nuclear Magnetic Resonance
(NMR). Unfortunately, the crystallization of almost all GPCRs is still an unresolved
problem [11].
Given the high-level of interest these proteins attract, it is not surprising that
predictive methods to derive information about their 3D-structure are essential.
An alternative approach to experimental methods is to build a molecular model of the
protein through the homology modelling (HM), [12] in which the target protein is
constructed starting from the experimentally known 3D-structure of related proteins.
The first high-resolution structure of a protein related to GPCRs was published for
bovine rhodopsin [13], thus more reliable HM approaches for all the GPCRs begun to be
affordable. Recently, some other related proteins were resolved [14, 15, 16]. Below in the
section 3.2.1, all the available crystallographic structures would be reported.
2.3. Angiotensin II receptor blockers (ARBs)
The initial target for developing compounds that could inhibit the renin-angiotensin
pathway was the angiotensin II octapeptide (Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8).
Ang-II plays a key role in the regulation of cardiovascular homeostasis. Acting on both the
“content” and the “container”, Ang-II regulates blood volume and vascular resistance.
The wide spectrum of Ang-II target tissues includes the adrenals, kidney, brain, pituitary
gland, vascular smooth muscle, and the sympathetic nervous system.
Angiotensin II receptor blocker (ARBs) are designed to displace angiotensin II from
the AT1 receptor and produce their blood pressure–lowering effects by antagonizing
angiotensin II–induced vasoconstriction, aldosterone release, catecholamine release,
arginine vasopressin release, water intake, and hypertrophic response [17].
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Efforts to develop angiotensin II receptor antagonists began in the early 1970s and
focused on peptide-based analogues of the natural agonist. The prototypical compound
that resulted from these studies was saralasin, an octapeptide in which the Asp1 and
Phe8 residues of angiotensin II were replaced with Sar (sarcosine, N-methylglycine) and
Ile, respectively. Saralasin, as well as other peptide analogues demonstrated the ability to
reduce blood pressure. However, these compounds lacked oral bioavailability and has to
be administered intravenously [18], and it has behaved as a partial agonist [19].
More recent efforts have used peptide mimetics to pass over these inherent
problems with peptide-based antagonists. In early 1980s it was noted that a series of
imidazole-5-acetic acid derivatives decreased blood pressure responses to Ang-II in rats.
Two compounds, S-8307 and S-8308 [20], were later found to be highly specific and
promising non-peptide Ang-II receptor antagonists, but afterwards it was seen that their
structures would have to mimic more closely the pharmacopoeia of Ang-II. Structural
modifications were made and the orally active, potent and selective non-peptide AT1
receptor blocker losartan was developed. As a result of these efforts in 1995, losartan first
to be approved for clinical use in the United States and since then seven additional ARBs
have been approved [21, 22] (Table 1).
Losartan, developed to mimic a natural peptide Ang-II, shares common structural
features with it. The imidazole ring of losartan correlated with the imidazole side chain of
the His6 residue, and the n-butyl group of losartan correlated with the hydrocarbon side
chain of the Ile5 residue. Valsartan, irbesartan, telmisartan, candesartan, olmesartan, and
azilsartan are biphenyl analogs of losartan.
Valsartan represents a nonheterocyclic AT1 receptor selective antagonist in which
the imidazole of losartan has been replaced by an acylated amino acid [23].
Irbesartan is a potent AT1 receptor antagonist that incorporates an imidazolinone
ring in which a carbonyl group functions as a hydrogen bond acceptor in place of the
hydroxymethyl group of losartan [24].
The benzimidazole, candesartan cilexetil, developed at Takeda Chemical
Industries, is an ester carbonate prodrug that is rapidly converted to the corresponding 7-
carboxylic acid, candesartan in vivo [25]. Candesartan is a potent, long acting selective
AT1 receptor, competitive insurmountable antagonist [26]. The carboxyl group at the
benzimidazole ring plays an important role in the interaction of candesartan with
AT1 receptor [27].
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Losartan Valsartan Irbesartan
Candesartan
Eprosartan
Telmisartan
Olmesartan Azilsartan
Table 1 – Structures of AT1 receptor nonpeptidic antagonists.
3. MODELLING THE AT1 RECEPTOR
3.1. Homology modelling methodology
Generally, the study of a protein’s function requires previous knowledge of its
three-dimensional structure [28, 29], which is ultimately determined by protein
sequence [30]. Protein structure determination using experimental methods, such as X-
ray crystallography or NMR spectroscopy is time consuming and not successful with all
proteins, especially membrane proteins [31]. The huge gap between the number of
available sequences and experimentally solved protein structures could possibly be
resolved by computational methods.
The homology modelling method predicts the three-dimensional structure of a
given protein sequence based primarily on its sequence similarity to one or more proteins
of known structures. It is also called comparative modelling or template-based modelling.
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Homology modelling methods use the fact that evolutionary related proteins share a
similar structure [32, 33]. A protein structure is always of great assistance in the study of
interactions with ligands within pharmaceutical industry in structure-based drug discovery
and drug design. Homology modelling can provide the molecular biologists and
biochemists with "low-resolution" structures, which will contain sufficient information about
the spatial arrangement of important residues in the protein and that may guide the design
of new experiments.
The protein under the query with unknown 3D structure is called the target.
Whereas, the protein or proteins with similar sequence and known 3D structure, that
would be used to predict the structure of the target protein is known as template protein or
proteins.
In practice, homology modelling is a multistep process that can be summarized in
four steps: 1) template selection; 2) target-template alignment; 3) model construction and
4) model assessment.
Step 1. Template selection
The sequence of similarity can be searched using BLAST or Psi blast or fold
recognition methods and align with the known structures in Protein Database (PDB). PDB
is the largest database that contains only experimentally resolved structures. BLAST
allows comparing a query sequence with a database, such as PDB and identifying the
best sequence that shares a high degree of similarity. The sequence of similarity of each
line is summarised with its E-value (Expected value). E-values closer to zero, have high
degree of similarity. The E-value describes the number of hits one can “expect” when
searching through a database of a particular size. The sequences that fall under safe
zone are expected to be getting good structure than twilight zone and midnight zone.
Step 2. Target-template alignment
After identifying one or more possible template, alignment is performed.
Sometimes it is difficult to align two sequences that have low percentage of identity. Such
cases, one can use other sequences from homologous proteins to solve this problem.
Multiple Sequence Alignment programs such as CLUSTALW [55] align sequences by
insertions and deletions. Alignment correction is the critical step in Homology Modelling,
otherwise which in turn creates a defective model.
Step 3. Model construction (Backbone generation)
a. Backbone generation
The backbone generation from the aligned regions can be done using modelling
tools such as Modeller [34]. The actual experimentally determined structures contain
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manual errors due to poor electron density in the map. Therefore a good model has to be
chosen with less number of errors.
Modeller is a program for comparative protein structure modelling by satisfaction of
spatial restraints [35]. It can be described as “Modelling by satisfaction of restraints” uses
a set of restraints derived from an alignment and the model is obtained by minimization of
these restraints. These restraints can be from related protein structures or NMR
experiments. User gives an alignment of sequences to be modelled with known
structures. Modeller calculates a model with all heavy atoms. It also performs comparison
of protein structures or sequences, clustering of proteins, searching of sequence
databases.
The highest sequence identity, observed for CXCR4 Chemokine receptor (34%), is
still small for basic safe homology modelling. Therefore, two more sophisticated
approaches were used for modelling: iterative modelling and advanced modelling.
Iterative modelling was introduced to overcome the problem in homology
modelling caused by limitation of errors in the alignment of a modelled sequence with
related proteins of known three-dimensional structure. Thus, it have been developed an
automated method that optimizes both the alignment and the model implied by it [36]. This
task is achieved by a genetic algorithm protocol that starts with a set of initial alignments
and then iterates through re-alignment, model building and model assessment to optimize
a model assessment score.
Advanced modelling, based on multiple templates, utilizes information from various
templates, and therefore “naturally” increases the accuracy of Homology Modelling,
presumably since it better captures the variability and divergence of natural structures.
b. Loop modelling
In most cases, alignment between model and template sequence contain gaps. By
means of insertions and deletions with some conformational changes to the backbone it
can be modelled, although it rarely happens to secondary structures. Therefore, it is safe
to shift the insertion and deletions of the alignment, out of helices or strands and placing
them in loops or coils. But this loop conformational change is difficult to predict due to
many reasons like:
1. Surface loops tend to be involved in crystal contacts, leading to a signiﬁcant
conformational change between template and target.
2. The interchange of the side chains can lead to change in the orientation and
spatial arrangement, especially when it is an interchange between small and a bulky
group.
3. Proline and glycine are an exception when a Ramachandran plot is considered.
Proline has a restriction in the plot due to its 5 membered ring, whereas glycine has a
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hydrogen atom as its side chain which is very difficult to predict from the plot. This makes
it difficult for detect mutations that have happened to loop residue from/to either glycine or
proline.
In Modeller, the loop modelling is based on the loop refinement – optimization
method for loop modelling. This method relies on a scoring function and optimization
schedule adapted for loop Modelling. It is used automatically to refine comparative models
if one uses the command from loopmodel class rather than automodel.
c. Side chain modelling
Proteins that are structurally similar, have similar χ1–angles (i.e., the torsion about
Cα-Cβ bond. In such cases, copying conserved residues entirely from the template to the
model will result in higher accuracy than copying the backbone or re-predicting side
chains. Side chain conformations are partially knowledge based which uses libraries of
rotamers extracted from high resolution X-ray structures. To build a position-specific
rotamer library, one can take high-resolution protein structures and collects all stretches of
three to seven residues (method dependant) with a given amino acid at the center.
Prediction accuracy is usually quite high for residues in the hydrophobic core, it is much
lower for surface residues.
There are two reasons for this:
1. Flexible side chains on the surface tend to adopt multiple conformations, which
are additionally influenced by crystal contacts.
2. Energy functions used to score rotamers can easily handle hydrophobic packing
in the core (Van der Waals interactions), but are not accurate enough to get complicated
electrostatic interactions on the surface.
d. Model optimization
Sometimes the rotamers are predicted based on incorrect backbone or incorrect
prediction. Such cases Modelling programs either restrain the atom positions and/or apply
only a few hundred steps of energy minimization to get an accurate value. This accuracy
can be achieved by 2 ways:
1. Quantum force field: To handle large molecules efficiently force field can be
used, energies are therefore normally expressed as a function of the positions of the
atomic nuclei only. Van der Waals forces are, for example, so difficult to treat, that they
must often be completely omitted. While providing more accurate electrostatics, the
overall precision achieved is still about the same as in the classical force fields.
2. Self-parametrizing force fields: The precision of a force field depends to a large
extent on its parameters (e.g., van der Waals radii, atomic charges). These parameters
are usually obtained from quantum chemical calculations on small molecules and fitting to
experimental data, following elaborate rules [37]. By applying the force field to proteins,
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one implicitly assumes that a peptide chain is just the sum of its individual small molecule
building blocks—the amino acids.
Step 4. Model assessment
The obtained models may contain errors, which mainly depend upon two values:
1. The percentage identity between the template and the target. If the value is
>90%, then accuracy can be compared to crystallography, except for a few individual side
chains. In this case sequence similarities are considered accurate enough for drug
discovery applications. If its value ranges between 50-90%, the root-mean square
deviation (RMSD) error can be as large as 1.5 Å, with considerably more errors. Those
between 25 and 50% identities can be helpful in designing of mutagenesis experiments. If
the value is <25% the alignment turns out to be difficult for Homology Modelling, often
leading to quite larger errors [38, 39].
2. The number of errors in the template. Errors in a model become less of a
problem if they can be localized. Therefore, an essential step in the Homology Modelling
process is the verification of the model. The errors can be estimated by calculating the
model’s energy based on a force field. This method checks to see if the bond lengths and
angles are in a normal range. However, this method cannot judge if the model is correctly
folded. The 3D distribution functions can also easily identify misfolded proteins and are
good indicators of local model building problems.
The prediction and assessment of protein structures can be enabled by accurate
free energy function [40]. The native structure generally has the lowest free energy of all
states under the native conditions. In principle, the free energy surface of a protein can be
derived by thoroughly sampling the potential energy surface defined by a molecular
mechanics force field [41]. However, this approach is computationally prohibitive and may
be further limited by errors in potential energy functions. Instead of relying on free energy,
an alternative approach is to construct a scoring function whose global minimum also
corresponds to the native structure from a sample of native structures of different
sequences [42] deposited in the Protein Data Bank. Due to its dependence on known
protein structures, such a scoring function is often termed a knowledge-based or statistical
potential. Such statistical potential was derived and implemented to the MODELLER
software, and is named as Discrete Optimized Protein Energy, or DOPE [43]. The DOPE
model score was designed for selecting the best structure from a collection of models built
by MODELLER software. For example, when the multiple models are built, one can select
the model that returns the lowest DOPE score.
Another way to assess the models is a GA341 assessment score, a score for the
reliability of a model, derived from statistical potentials [44]. GA341 scores always range
from 0.0 (worst) to 1.0 (native-like). A model is predicted to be reliable when the model
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score is higher than a pre-specified cutoff (0.7). A reliable model has a probability of the
correct fold that is larger than 95%. However GA341 is not as good as DOPE at
distinguishing 'good' models from 'bad' models.
3.2. Homology modelling of the AT1 receptor
Below, the structures that are used as templates for the target, found in the PDB,
are discussed.
Several attempts have been made to model the human AT1 receptor structure
using bacteriorhodopsin 3D structure [45, 46, 47] as a template. Because
bacteriorhodopsin is not class A GPCR, direct use of its structure to model the TM-domain
structure of the AT1 receptor is limited. Recent availability of bovine Rhodopsin (bRh) X-
ray structures made it possible to model the AT1 receptor. Below are reviewed these X-
ray structures.
Family of Bovine Rhodopsin receptor
In the year 2000, Palczewsky et al. reported the first high resolution structure of
bovine rhodopsin [13]. The structure with a 2.8 Å resolution can be found in the Protein
Data Bank (PDB) [48] with PDB ID 1F88 (Fig. 3a). This surely was a milestone towards
understanding of the structure of the other GPCRs and for the evolution of the HM
procedures.
Other high-resolution models of bRh, obtained using X-ray diffraction, have been
successively deposited in the PDB by Teller et al. – PDB ID 1HZX [49] (Fig. 3b), and by Li
et al. – PDB ID 1GZM [50] (Fig. 3c). The structures have comparable resolution to
PDB ID 1F88.
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a) b) c)
d) e)
Fig. 3 – Bovine rhodopsin receptor: a) 1F88, b) 1HZX, c) 1GZM, d) 1L9H, e) 1U19
a) b) c)
d) e) f)
Fig. 4 – Human kappa opioid receptor: a) 4DJH; human β2-adrenergic receptor: b) 2RH1, c) 3NY9; CXCR4 receptor:
d) 3ODU, e) 3OE0, f) 3OE9.
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Similarly, another structure was crystallised and published by Okada et al. –
PDB ID 1L9H [51] (Fig. 3d). This structure possesses the resolution of 2.6 Å, moreover, it
shows that seven water molecules bind some of the highly conserved residues among
rhodopsin-like GPCRs and are able to mediate intramolecular interactions between the
seven TM domains. Therefore this 3D structure is to be considered of particular
importance for the GPCR HM development.
More recently, a new structure (1U19 [52], Fig. 3e) has been available in the PDB.
It was crystallised under different conditions, allowing an improvement of the quality of the
HM template structure because the resolution was reduced to 2.2 Å.
Family of human kappa opioid receptor
In 2012, another structure from the family of GPCR receptors – human kappa
opioid receptor (4DJH [53], Fig. 4a) has been resolved and deposited to the PDB.
Family of human β2-adrenergic receptor
The crystal structure of one of the most extensively studied receptors – human β2-
adrenergic receptor (2RH1 [14], Fig. 3f) – was reported by Cherezov et al. The structure
provides a high-resolution (2.4 Å) view of a human G protein-coupled receptor bound to a
diffusible ligand. More recently, another 3D structure of the same receptor in complex with
two inverse agonists (3NY9 [15]) was resolved by Wacker et al.
Family of CXCR4 receptor
The branch of γ-GPCR includes available crystallographic structures. In particular,
the CXCR4 receptor retains most of the common GPCR structural characteristics,
whereas the fourth transmembrane domain (TM4) differs in length as it forms an extra α-
helix turn near extracellular part. Wu et al. [16] reported about independent crystal
structures of CXCR4 bound to an antagonist small molecule IT1t and a cyclic peptide
CVX15 at 2.5 to 3.1 angstrom resolution (3ODU, 3OE0, 3OE9).
The sequences that are necessary for sequence alignment were obtained from the
SwissProt Database [54].
All possible templates, used in this study, are summarized below in the Table 2.
The table includes the name of the receptor, PDB code, sequence identity code, and X-
Ray resolution.
The initial multiple sequence alignment was performed using ClustalW as provided
on the EBI webserver [55]. The program compares the query sequence to the template
sequences of known structures.
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Template Receptor Sequence
(UniProt)
PDB code X-Ray
Resolution
1. Bovine Rhodopsin P02699 1F88 2.80 Å
1U19 2.20 Å
1GZM 2.65 Å
1HZX 2.80 Å
1L9H 2.60 Å
2. Kappa-type opioid receptor P41145 4DJH 2.90 Å
3. Beta-2 adrenergic receptor P07550 2RH1 2.40 Å
3NY9 2.84 Å
4. CXCR4 Chemokine receptor P61073 3ODU 2.50 Å
3OE0 2.90 Å
3OE9 3.10 Å
Table 2. Available target templates
In the Table 3 below, the results of multiple alignments are presented in the order
from the highest to lowest sequence identity percentage. One is interested in the highest
values – the highest similarity between the template and the target proteins. The highest
sequence identity is observed for CXCR4 Chemokine receptor – 34%. This is followed by
Kappa-type opioid receptor (29%), Beta-2 adrenergic receptor (21%), and Bovine
Rhodopsin with 20%.
Template Receptor Sequence
identity
PDB code X-Ray
Resolution
1. CXCR4 Chemokine receptor 34% 3ODU 2.50 Å
3OE0 2.90 Å
3OE9 3.10 Å
2. Κ-opioid receptor 29% 4DJH 2.90 Å
3. β2 adrenergic receptor 21% 2RH1 2.40 Å
3NY9 2.84 Å
4. Bovine Rhodopsin receptor 20% 1F88 2.80 Å
1U19 2.20 Å
1GZM 2.65 Å
1HZX 2.80 Å
1L9H 2.60 Å
Table 3. The percentage of the sequence identity for each template protein.
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In the Fig. 5 the multiple sequence alignment between the target receptor AT1 and
the template receptors are presented. The initial alignment was manually adjusted to best
satisfy the position of residues conserved throughout class A GPCR’s [56]. Any gaps were
avoided in the trans-membrane helices and instead placed in the loop and termini regions.
Fig. 5. Multiple sequence alignment between the target receptor AT1 and the template receptors, performed in
CLUSTAL 2.1 [55].
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The Homology Modelling protocol will proceed to arrange the backbone of the target
sequence according to that of the template, using the sequence alignment to decide
where to position each residue. Therefore, the quality of the sequence alignment is of
crucial importance. Misplaced indels (gaps representing insertions or deletions) will cause
residues to be misplaced in space. Although the routine used does alignments
automatically, careful inspection and manual adjustment may improve the quality of the
alignment, and hence, of the homology model.
After the multiple alignments were done, it was decided to perform iterative
modelling on the base of each template, and advanced modelling on the base of multiple
structures of the same template. Thus, it was done four iterative modelling protocols, and
three advanced modelling protocols (kappa-type opioid receptor has only one available X-
ray structure; therefore it hasn’t been involved in multiple template construction).
Five models were produced from the four templates in iterative modelling, and
5 models were produced from each group of available structures from three templates in
advanced modelling, so in total 35 models. The next step was to select the “best” models.
Iterative modelling Advance modelling
1. On the base of CXCR4 Chemokine
receptor template
1. On the base of 3 structures of CXCR4
Chemokine receptor
Model
name
DOPE
score
GA341
score Model name
DOPE
score
GA341
score
Model.It.1.1 -40877.5 0.95395 Model.Adv.4.1 -41308.8 0.99993
Model.It.1.2 -40389.2 0.95677 Model.Adv.4.2 -40507.5 0.99986
Model.It.1.3 -41117.5 0.98503 Model.Adv.4. 3 -41484.0 0.99999
Model.It.1.4 -41491.1 0.94713 Model.Adv.4. 4 -40401.9 0.98810
Model.It.1.5 -41117.0 0.96780 Model.Adv.4. 5 -40988.4 0.99831
2. On the base of β2 adrenergic
receptor template
2. On the base of 2 structures of β2
adrenergic receptor
Model
name
DOPE
score
GA341
score Model name
DOPE
score
GA341
score
Model.It.3.1 -38933.3 0.29955 Model.Adv.2.1 -42005.4 0.31227
Model.It.3.2 -38603.6 0.20276 Model.Adv.2.2 -40786.3 0.40978
Model.It.3.3 -38722.4 0.26280 Model.Adv.2.3 -41166.9 0.44090
Model.It.3.4 -38693.0 0.26446 Model.Adv.2.4 -40365.5 0.30343
Model.It.3.5 -38068.8 0.17337 Model.Adv.2.5 -41142.7 0.36918
3. On the base of Bovine Rhodopsine
receptor template
3. On the base of 5 structures of Bovine
Rhodopsin receptor
Model
name
DOPE
score
GA341
score Model name
DOPE
score
GA341
score
Model.It.4.1 -43537.9 0.05072 Model.Adv.3.1 -42766.7 0.11459
Model.It.4.2 -43143.4 0.12643 Model.Adv.3.2 -43578.2 0.12359
Model.It.4.3 -42829.2 0.12070 Model.Adv.3.3 -43066.8 0.07247
Model.It.4.4 -42785.0 0.18405 Model.Adv.3.4 -43180.9 0.07225
Model.It.4.5 -43119.8 0.13055 Model.Adv.3.5 -42507.0 0.09612
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4. On the base of K-type opioid
receptor template
Model
name
DOPE
score
GA341
score
Model.It.2.1 -37661.7 0.88938
Model.It.2.2 -37896.0 0.93322
Model.It.2.3 -37236.1 0.61869
Model.It.2.4 -37626.6 0.83868
Table 4. The summary of the successfully produced models.
After the assessment by DOPE and GA341 scores was done, and 7 best models
were chosen, they were further assessed by the quality of secondary structure by
calculating Ramachandran plot [57] for the whole protein. A Ramachandran plot is a way
to visualize backbone dihedral angles ψ against φ of amino acid residues in protein
structure. The quality of secondary structure elements was tested by using the definitions
introduced by Morris et al. for the allowed and disallowed regions for φ and ψ angles of
the backbone that reflects the stability of protein structure [58]. Basically, this analysis
helps to say which protein model is better. The more amino acid residues fall into allowed
region, the better the model. After Ramachandran-plot analysis of the chosen models,
there were chosen 2 models: one from iterative modelling on the base of one chemokine
receptor template – model 1, and one from advanced modelling on the base of three
chemokine receptor templates – model 2. Their plots are presented on the Fig. 6. Model 1
has 93% of the residues in the allowed region, while model 2 has 94%.
Fig 6. – Ramachandran plot: a) model 1; b) model 2.
Force-field minimization in AMBER: After two models were chosen, they were
optimised with molecular mechanical level of theory in the Amber software [59]. Each of
the modelled receptors was placed to the box, the faces of which are 12 Å distant from the
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protein, and the boxed was filled with explicit water molecules (TIP3PBOX) with xleap
program (Fig. 7). Chlorine or sodium counter ions were added to keep the system neutral.
The relaxation was carried out in three steps. In a first phase only the geometry and
position of the water molecules were minimized by keeping the rest of the system fixed.
This step aims to reduce possible unfavourable interactions caused by automated
placement of water molecules by xleap program. In a second step the position of the
hydrogen atoms was optimized, while maintaining the other atoms fixed. At third step the
position of all atoms of the model was optimized. The Force Field used was parm99SB,
specifically created for proteins.
The disulfide bonds were formed between Cys101 in TM3 and Cys180 in
extracellular-loop 2 by covalently bound their sulphur atoms (Fig. 7). Globally, we have
performed energy minimizations with the AMBER force field to allow the protein atoms to
relax and adjust.
Fig. 7 – Force-field minimization in AMBER: a) AT1 receptor in the water box; b) modelled AT1 receptor with the conserved
disulphide bond Cys101-Cys180 (magenta and yellow).
After energy minimization was done, the models were visually checked. The
following residues experimentally shown to be involved in Ang-II binding, Lys199, Asn111,
His256, Gln257, Asn294, Asn295 and Asn298, are indeed pointing inward. The analysis
of interactions would provide a clear understanding which model would be preferable in
further studying after molecular docking calculations would be performed.
Now, the models are ready to proceed with the next step of study – Molecular
Docking.
a) b)
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4. MOLECULAR DOCKING
4.1 Protein-Ligand Docking methodology
Molecular docking is a widely used computer simulation procedure to predict the
structure of the intermolecular complex formed between two or more constituent
molecules, and tries to distinguish, from the energy point of view, binding mode of such
complex, i.e. pose that maximizes the binding energy of interaction while minimizing the
total energy of the complex. The accurate prediction of the binding poses between the
ligand and protein is of fundamental importance in modern structure-based drug design.
The present study is related to the protein-ligand docking. The protein-ligand
docking tries to predict the position and orientation of a ligand (a small molecule) when it
is bound to a protein, enzyme or receptor (macromolecule). In our study we docked the
natural peptide Ang-II and known inhibitors to a modelled receptor AT1 (Fig. 9).
Modelling the interaction of two molecules is a complex and challenging problem.
Many forces are involved in the intermolecular association, including hydrophobic, van der
Waals, or stacking interactions between aromatic amino acids, hydrogen bonding, and
electrostatic forces. Modelling the intermolecular interactions in a ligand-protein complex
is difficult since there are many degrees of freedom as well as insufficient knowledge of
the effect of solvent on the binding association. The process of docking a ligand to a
binding site tries to mimic the natural course of interaction of the ligand and its receptor
via the lowest energy pathway. There are simple methods for docking rigid ligands with
rigid receptors, and flexible ligands with rigid receptors. However, methods of docking that
considers conformationally flexible ligands and receptors are problematic, as well as,
large time and computationally consuming. Therefore, in our study an approach to
consider the ligand flexibility while assuming having a rigid protein receptor was used.
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Fig. 8 – Representation of the Protein-Ligand Molecular Docking
Docking protocols can be described as a combination of a search algorithm, and
the scoring functions. The search algorithm should create an optimum number of
configurations that include the experimentally determined binding modes. Although a
rigorous searching algorithm would go through all possible binding modes between the
two molecules, this search would be impractical due to the size of the search space and
amount of time it might take to complete. As a consequence, only a small amount of the
total conformational space can be sampled, so a balance must be reached between the
computational expense and the amount of the search space examined. On the other
hand, scoring function consists of a number of mathematical methods used to predict the
strength of the non-covalent interaction called the binding affinity. In all the computational
methodologies, one important problem is the development of an energy scoring function
that can rapidly and accurately describe the interaction between the protein and ligand.
Over the course of the last years, different scoring functions have been developed that
exhibit different accuracies and computational efficiencies. Some of these commonly-used
functions are: force-field, empirical, knowledge-based and consensus scoring.
Ligand Target
Molecular Docking
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The molecular docking study was performed using software AutoDock v.4.0 [60].
This software contains a package of automated tools that were designed to predict how
small molecules, such as substrates or drug candidates, bind to a receptor with given 3D
structure.
AutoDock consists of two main programs: AutoDock that performs the docking of
the ligand to a set of grids describing the target protein, and AutoGrid that pre-calculates
these grids. In order to optimise the creation of the input files that were required to run
AutoDock and AutoGrid, the VsLab plug-in [61], which was written in the group of
Theoretical Chemistry and Computational Biochemistry of the University of Porto, was
used. VsLab is an easy-to-use and freely available graphical interface for the molecular
docking software AutoDock that has been included into VMD as a plug-in.
AutoDock offers a variety of search algorithms to explore a given docking problem.
These include Monte Carlo Simulated Annealing (SA); a Genetic Algorithm (GA); and a
hybrid local search GA, also known as the Lamarckian Genetic Algorithm (LGA). In
general, the LGA performs the best out of SA, GA, and LGA, in finding the lowest energy
of the system. We chose LGA algorithm for our studies.
4.2 Docking of the angiotensin II to the model of the AT1 receptor
After two models of the AT1 receptor were prepared for the study of docking, Ang-
II was docked to both models following the same procedure. The octapeptide Ang-II was
docked to the docking area that includes the binding pocket according to known site-
directed mutagenesis data [62, 63, 64, 65]. The parameters of the docked box, used in the
study on the base of known interactions, were as following: width 25.87 Å; height:
26.625 Å; depth: 31.5 Å. Number of grid points at X, Y, Z: 66, 76, 89, with grid spacing of
0.375 Å (Fig. 9).
The ligand, peptide hormone, Ang-II was obtained from the PDB (PDB code
1N9V).
As can be seen from the representation of the docked Ang-II to the modelled
AT1 receptor (Fig. 9), it is nestled between TM helices.
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Fig. 9 – Representation with the box of the docking area of the AT1 receptor (blue), and docked Ang-II (yellow).
All the docking poses of Ang-II to the AT1 receptor were analysed for binding site
to choose the best model. The results of docking showed better results for the second
model (on the base of multiple structures of the chemokine receptor). The discussions of
docking are presented below. This model was used in further analysis – docking of the
inhibitors.
Table 5 contains solutions of the docking of the ligand with corresponded energy
score that is the Gibbs energy of interaction. The lower the value the stronger ligand is
bound to the receptor. The dissociation constants were calculated as well.
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Ligand (S#, docking solution number) Score Ki(M)
AngII-S1 -10.46 2.15·10-08
AngII-S2 -8.79 3.60·10-07
AngII-S3 -8.40 6.95·10-07
AngII-S4 -8.19 9.91·10-07
AngII-S5 -8.18 1.01·10-06
AngII-S6 -6.60 1.45·10-05
AngII-S7 -6.58 1.50·10-05
AngII-S8 -6.47 1.81·10-05
AngII-S9 -6.40 2.03·10-05
AngII-S10 -5.34 1.22·10-04
Table 5 – Solutions of the docking of Ang-II to the model of the AT1 receptor, with corresponding energy scores, and
dissociation constants.
The best docked solutions were visualised thoroughly with VMD, whether they
fulfilled known experimental data (mainly the interaction of the carboxyl terminal with
Lys199, and Arg167). The first complex, which showed the better and most stable binding
free energy value, was chosen for further investigation, and the interactions of which are
described.
As presented on Fig. 10, the representative binding conformation of Ang-II shows
a hydrogen bond interaction between Lys199 in TM5 and the carboxyl terminal of the
peptide (Phe8). The distance between oxygen of the carbonyl terminal of the peptide and
NH3 group of Lys199 of the AT1 receptor are 2.64 Å and 2.88 Å. Another important
interaction was found between the carboxyl terminal of the peptide (Phe8) and Arg167 in
TM4 of the AT1 receptor. This interaction is critical, since studies have showed an almost
complete loss of Ang-II affinity when Arg167 was mutated [66, 67]. In the present
homology model, Arg167 points to the binding site core (Fig. 10). And the distance
between oxygen of the carboxyl terminal of the peptide (Phe8) and NH2 group of Arg167
of the AT1 receptor are 3.32 Å and 4.18 Å. The interaction of His256 with Phe8 (Fig. 10)
known to be critical for Ang-II activation is a stacked attraction of aromatic rings [68, 69,
70]. In the present homology model the rings are oriented parallel to each other with the
distance approximately of 6.00 Å.
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Fig. 10 – Representation of the predicted binding site of Ang-II (licorice) in the AT1 receptor (NewCartoon
magenta). Residues Lys199, Arg167, and His256 of AT1 receptor are represented in CPK. The distance unit is specified in
angstroms.
The Phe8 bulky ring of Ang-II is oriented towards the highly hydrophobic pocket
formed by residues Ala104, Val108, Phe77, Leu81, Trp253, Leu112, Tyr292, Phe182,
Trp84, Met284, Ile288 of the AT1 receptor (Fig. 11).
Fig. 11 – Representation of the Phe8 of Ang-II (yellow) in the hydrophobic pocket formed by residues Ala104,
Val108, Phe77, Leu81, Trp253, Leu112, Tyr292, Phe182, Trp84, Met284, Ile288 of the AT1 receptor.
Arg2 interacts with the charged side chain of Asp263 (Fig. 12). Asp263 mutation
has also been reported to almost abolish binding of the antagonistic peptide [Sar,Ile]Ang-II
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to the AT1 receptor [71]. The distances between oxygen of Asp263 and NH2 group of
Arg2 are 1.83 Å and 3.23 Å. Asp281, which have been documented as important for full
agonism of Ang-II, interacts with Tyr4 and Ile5 of Ang-II. The suggested orientation of Tyr4
and Ile5 towards TM7, by forming polar interactions with D281, has been also reported
recently [72].
Fig. 12 – Representation of the interaction between Tyr4 and Ile5 of Ang-II and Asp281 of the AT1 receptor, and
the interaction between Arg2 of Ang-II and Asp263 of the AT1 receptor. The distance unit is specified in angstroms.
4.3 Docking of the known inhibitors to the model of the AT1 receptor
Each of non-peptide inhibitors (Table 1) was docked to the same docking area as
was used for Ang-II. The geometries of non-peptide ligands were obtained from
ChemSpider database and the DrugBank database [73, 74].
The predicted binding pose of the inhibitor losartan matches very well with
available site-directed mutagenesis data, and is presented on the Fig. 13. Lys199 creates
a weak hydrogen bond interaction with the losartan hydroxyl group (4.01 Å), while the
tetrazole ring is cradled between Tyr184 and Leu195 (3.91 Å and 2.22 Å, respectively).
The central phenyl rings are stabilized by pi-stacking, one with Tyr113, and another with
Phe182. Imidazole ring of losartan is stabilized with hydrogen bond with Tyr292 (3.32 Å).
The important residue His256 also interacts with a hydroxyl group (2.03 Å).
Arg2
Asp263
Asp281Ile5
Tyr4
3.23 1.83
2.77
3.91
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Fig. 13 – Representation of the predicted binding site of losartan in the AT1 receptor. The distance unit is
specified in angstroms.
The predicted binding site for cardesartan (Fig. 14) is similar to that one of
losartan. The carboxyl group of the inhibitor creates hydrogen bonds with residues Lys199
and His256 (4.28 Å and 1.72 Å, respectively). Tetrazole ring of the inhibitor is stabilized by
Fig. 14 – Representation of predicted binding site of candesartan in the AT1 receptor. The distance unit is
specified in angstroms.
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pi-stacking with Tyr113 (the rings are on the distance around 5.0 Å), and by the interaction
with hydroxyl group of Ser105 (4.39 Å). Central ring is stabilized by pi-stacking with
Phe182.
The representative binding conformation of olmesartan is depicted on Fig. 15. The
predicted binding pocket is similar to the previous non-peptide inhibitors, but in this case
Lys199 is not in good orientation to the carboxyl group, but still quite close on the distance
of 3.90 Å to it. The same carboxyl group, again as in previous inhibitors, is stabilized by
carboxyl group of His256 (2.51 Å). Tetrazole cycle is stabilized by pi-stacking with Tyr113
(the distance is around 5.50 Å), and by interaction with Ser105 (4.30 Å), while phenyl
cycle is stabilized by pi-stacking with Phe182 (distance around 4.50 Å).
Fig. 15 – Representation of predicted binding site of olmesartan in the AT1 receptor. The distance unit is specified
in angstroms.
The predicted binding site for eprosartan is in a good agreement with previous
results. Lys199 is in good orientation and close to the carboxyl group creating an
interaction with it (1.82 Å). Ser105 stabilizes the imidazole ring (4.88 Å), while His256
stabilizes carboxyl groups (3.17 Å and 2.03 Å). Phenyl cycle is stabilized by pi-stacking
with Trp253 (4.50 Å), while imidazole is pi-stacked with Phe182 (4.00 Å).
Lys199
Ser105
Phe182
Tyr113
His256
2.51
3.904.30
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Fig. 16 – Representation of predicted binding site of eprosartan in the AT1 receptor. The distance unit is specified
in angstroms.
The predicted binding pose of the inhibitor irbesartan (Fig. 17) includes interaction
between hydroxyl group of Tyr184 and tetrazole (2.07 Å and 2.08 Å). Imidazole ring is
stabilized by hydroxyl groups of Tyr113 and Ser109 (2.23 Å and 2.67 Å). Lys199 is close
but as in the case of olmesartan is not in good geometrical orientation. Phenyl cycle is
stabilized by pi-stacking with Phe182 (6 Å).
Fig. 17 – Representation of predicted binding site of irbesartan in the AT1 receptor. The distance unit is specified
in angstroms.
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Docking of the inhibitor telmisartan revealed the binding site similar to the previous
inhibitors (Fig. 18). The carboxyl group of the inhibitor has interactions with Lys199 and
His256 (5.72 Å and 2.39 Å, respectively), while imidazole cycle has interactions with
hydroxyl groups of Tyr113 (2.05 Å) and Ser109 (3.16 Å). Stabilization of phenyl cycle
again occurs through pi-packing with Phe182.
Fig. 18 – Representation of predicted binding site of telmisartan in the AT1 receptor. The distance unit is specified
in angstroms.
The representative binding conformation of valsartan is shown in Fig. 19. Carboxyl
group of the inhibitor interacts with Lys199 (3.37 Å) and His256 (2.78 Å). Imidazole cycle
Fig. 19 – Representation of predicted binding site of valsartan in the AT1 receptor. The distance unit is specified
in angstroms.
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is in between hydroxyl groups of Tyr113 (3.59 Å) and Tyr184 (5.23 Å). Phenyl cycle is pi-
stacked with Phe182 (5.00 Å).
The predicted binding pose of the last inhibitor azilsartan has a similar pose as the
inhibitors described above. The carboxyl group of azilsartan is cradled between Lys199
and His256 (3.30 Å and 3.67 Å, respectively), Asp263 creates a hydrogen bond
interaction with hydrogen of imidazole heterocycle (2.29 Å), Tyr184 creates a hydrogen
bond interaction with a terminal heterocycle (2.21 Å), the same ring is stabilized by pi-
stacking with Phe182 (3.50 Å).
Fig. 20 – Representation of predicted binding site of azilsartan in the AT1 receptor. The distance unit is specified
in angstroms.
According to the docking results, the important residues of the binding pocket that
interacts with inhibitors are Lys199 and His256, creating hydrogen bonds with carboxyl
groups, Phe182 that stabilizes phenyl cycles by pi-stacking, Tyr113 and Ser109 in
majority of the cases show interaction with the carboxyl group. Tyr184 is often interactions
with inhibitors.
Below in the Table 6 are summarized Gibbs energies (∆G) obtained from the
docking calculations, as well as experimental values found in the PubMed database [75].
The inhibitors are ranked according to the energy score. The results are reasonably in
accordance with the experiment.
Asp263
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№
Inhibitor
Calculated
∆G
(kcal/mol)
Experiment
al ∆G
(kcal/mol)
1 Telmisartan -11.20 -11.50
2 Azilsartan -9.02 -
3 Irbesartan -8.63 -11.87
4 Eprosartan -8.62 -
5 Olmesartan -8.19 -13.70
6 Candesartan -8.03 -11.6
7 Valsartan -7.84 -10.4
8 Losartan -7.80 -9.58
Table 6 – Ranking of the inhibitors by their Gibbs energy values.
The obtained results of the docking validate the docking protocol. And the same
protocol can be used for further investigation.
Conclusions
In the current study insights for the design of novel drugs for hypertension were
provided by applying computational chemistry approach. Homology Modelling was applied
to create a model of the 3D structure of the AT1 receptor. The binding poses of
Angiotensin II to this receptor, which is an actual cause of the high pressure in the
organism, were determined using Molecular Docking. The docking protocol was validated
by docking of several AT1 antagonists to the created model of the AT1 receptor. This
protocol can be used in the future investigation of obtaining novel AT1 receptor blockers
using Virtual Screening.
5. PROSPECTIVE FOR THE FUTURE
After the 3D structure of the target AT1 receptor was obtained through Homology
Modelling technique and the protocol was validated with Molecular Docking, it is ready to
be used in the next step of drug development – hit identification.
Hit identification – is a docking methodology, combined with a scoring function that
can be used to quickly screen large databases of potential drugs in silico to identify
molecules that could interact with a target, or have similar properties to known ligands,
and become a promising hit or lead compound. Afterwards these presumed molecules
can be synthesized, tested and optimized in the laboratory. These types of methodologies
are commonly known as Virtual High Throughput Screening or simply Virtual
Screening (VS). VS is revealed as an important tool in drug development of novel drugs.
There is a wide range of methodological protocols available in screening databases for
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the lead compounds. The number of methods and software packages which employ the
target and ligand based virtual screening are increasing rapidly, making of high interest
the applicability of various virtual screening methods in the new lead identification and
optimization.
In the current project, afterwards the databases will be screened against the AT1
model in order to find lead compounds. There are many available databases in the net,
free of charge that can be used. One of particular interest is ZINC database [76] that
contains over 13 million purchasable compounds for virtual screening. Subsequently, the
hits obtained from the virtual screening have to be docked to the receptor model, and
best-scored structures of the system receptor – ligand would be subjected to Molecular
Dynamics simulations. Having identified the best candidates, they could be proceeding
with lead optimization. The information obtained from the study may in turn be used to
design more potent and selective analogues. Appropriate size and electrophilicity
substituents will be placed to complement the morphology and electrostatics of the
binding pockets.
Virtual Screening often requires careful preparation of both target and compound
library, use of optimal parameters as well as careful analysis of the results. That is why
the careful testing of the model of the AT1 receptor was done.
In the further study, the validated docking protocol would be applied to the ZINC
database [76]. To screen for a compounds that can bind to the created model of the
AT1 receptor, and in future can be a potential lead compounds for hypertension.
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II. THE MODELLING OF THE ENZYME
PATGMAC SYSTEM
1. INTRODUCTION
In the second part of the work and in order to learn other computational
methodologies, there was performed the preparation of the enzyme macrocyclase PatG
(PatGmac) system for the study of its catalytic mechanism. This will be useful to
characterise and potentially adapt their functions for use in the production of novel cyclic
peptides. This enzyme catalyses the macrocyclization of linear peptides designated
"patellamides” [77, 78].
The largely unexplored world of marine natural products has attracted the attention
of biologists and chemists over the past decades. Marine organisms elaborate
pharmaceutically useful compounds, therefore are a recognized source of diverse
biologically active molecules.
Patellamides, members of the cyanobactin family, were isolated from the ascidian
Lissoclinum Patella [79, 80, 81]. L. patella harbours an obligate symbiont, Prochloron
didemni, which has the necessary genes to produce patellamides, cyclic peptides that
display a versatility of biological activities such as cytotoxicity, and the ability to reverse
multiple-drug resistance in human leukemia cells [82, 83]. This makes these compounds
very attractive in becoming potential drugs in cancer treatment. But to date their
production has proven challenging for synthetic chemists.
R1 R2 R3 R4 Sequence
1 Pat A CHMeEt CHMe2 CHMeEt CHMe2 ITVCISVC
2 Pat B CH2CHMe2 CHMeEt CHMeEt CH2Ph LTICITFC
3 Pat C CHMe2 Me CHMeEt CH2Ph VTACITFC
4 Pat D CHMeEt Me CHMeEt CH2Ph ITACITFC
5 Pat E CHMe2 CHMe2 CHMeEt CH2Ph VTVCITFC
6 Pat F CHMe2 CHMe2 CHMe2 CH2Ph VTVCVTFC
7 Pat G CHMeEt Me CH2CHMe2 CH2Ph ITACLTFC
Fig. 21 – Structures of the known patellamides isolated from L. patella and their peptide sequences [83].
The patellamides are cyclic octapeptides containing highly conserved thiazole and
oxazoline and D-stereo centres (Fig. 21). The patellamides are derived from a precursor
peptide, PatE, which undergoes several modifications, catalysed by the enzymes PatA, B,
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C, D, F and G, to form the final cyclic peptide (macrocycle). These modifications include
heterocyclisation, proteolysis, oxidation and macrocyclisation.
2. BIOSYNTHESIS OF PATELLAMIDES
The biosynthesis of such patellamides is complicated, with many steps. In brief,
the patellamides are produced by a microcin-like biosynthetic pathway in which the
precursor peptide gene (patE) directly encodes the amino acid sequence of the
patellamide product(s). The post-translational modification machinery encoded by the
other genes in the cluster, then act on this precursor peptide to give the fully processed
cyclic peptide(s). The leader sequence of the precursor peptide PatE was assumed to
target it toward the post-translational machinery (scheme on the Fig. 22). The cyclic-
peptide sequences within the precursor peptide are flanked by start/stop recognition
motifs that recruit enzymes for post-translational modifications. PatGmac has been
reported to recognize the C-terminal macrocyclization signature AYDG [84]. The
sequence of the biosynthetic events suggested by Schmidt et al. [80] starts with the
heterocyclisation by PatD2 to form the oxazoline and thiazoline rings. Thiazoline is then
oxidised to thiazole by PatG1. Cleavage of the mature PatE could occur under the
influence of PatG2 or PatA, followed by adenylation by PatD1 and macrocyclisation, which
could be spontaneous or enzymatically controlled.
Fig. 22 – Scheme of suggested biosynthetic pathway for patellamide [81].
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3. PROPOSED MECHANISM FOR MACROCYCLIZATION
In the current project we aim to prepare the system for studying the step of
macrocyclisation. The macrocyclization is carried out by the catalytic triad Asp548-His618-
Ser783. The proposed mechanism (Fig. 23) consider nucleophilic attack of the serine of
the active site to the carbon of carbonyl with forming enzyme-substrate intermediate.
Subsequently, the four stop recognition residues AYDG are cleaved and N terminus of the
substrate comes to close the peptide and form a cycle.
Fig.23 – Proposed mechanism for macrocyclization [82].
4. MODELLING OF THE SYSTEM
To date, the structure of the PatG macrocyclase domain (359 residues) have
solved and its complex with a substrate mimic (12 residues, 9 resolved), highlighting the
key interactions which enable macrocyclisation over standard proteolysis [77]. Hence, we
started the modelling from this experimentally obtained complex of the enzyme and a
substrate mimic (PDB code: 4AKT), and free enzyme PatGmac (PDB code: 4AKS). The
great difficulty was to model the native and correct substrate inside the enzyme. Since the
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X-Ray structure contains inside the enzyme a mimic propeptide not yet subjected to the
microcylasation and epimerisation, and we need a correct substrate. The natural PatD
propeptide has the following sequence: Ile-Thr-Ala-Cys-Ile-Thr-Phe-Cys Ala-Tyr-Asp-Gly.
In the experiment, the mimic peptide has the sequence Val-Gly-Ala-Gly-Ile-Gly-Phe-Pro
Ala-Tyr-Asp-Gly. Four residues Ala-Tyr-Asp-Gly in both substrates are recognition signal
residues. Presumably, proline mimics the five-membered ring of the heterocycle in the
natural product. In Fig. 24 the X-ray structure (a), and the system with correct substrate
(b) after modelling are presented.
Fig. 24 – The representation of: a) the X-ray structure of the substrate-enzyme complex; b) the corrected structure of the
substrate-enzyme complex.
First, we started from the correction of the active site. In the X-ray structure, the
His618 of the active-site triad in the substrate-enzyme complex was substituted by Ala.
However, in the free enzyme the correct residues were used. The structure of the free
enzyme was superimposed with the structure of the complex, and the coordinates of the
atoms of the residue of Ala618 were replaced by the coordinates of the atoms of the
correct residue His618 in the complex.
After that, the loop (residues 651 – 657), missing in X-ray structure, was modelled
in MODELLER [35].
Then, we started with correcting the substrate of the complex. The idea was to
conserve the position of the most of the residues in the substrate and model missing
parts. In the experiment, the peptide not yet converted to microcylisation was used. We
were interesting in the system of the complex substrate-enzyme with already converted to
oxidation and epimerization changes. Besides, in the experiment was used initially not
correct substrate – prolines were used to mimic heterocycles, and the epimerisation
centres were not correct. We started from taking off the coordinates of the substrate. After
a) b)
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correcting the heterocycles, and modelling in the software Gausview [85] the missing
parts, we transfer back the substrate to the corrected enzyme. After that, the whole
system were minimized in Amber in 3 steps, in order to relax the system, removed the
tensions and clashes of the new substrate, and adding the loop and correction of the
active site.
5. QM/MM OPTIMIZATION
When the system was optimized in Amber, we proceed with the optimization in
ONIOM QM/MM.
The QM/MM method is a hybrid quantum mechanical/molecular mechanics
method. This scheme permits to divide the system into different regions that can be
studied with different level of theory such as ab initio, DFT, semi-empirical and molecular
mechanics, to produce reliable geometries and energies at reduced computational time.
In ONIOM QM/MM the energy of the full model system is calculated at the
MM level. Then the energy of the small model (the region of interest) is subtracted at the
MM level and added at the QM level (Fig. 25).
Fig. 25 – ONIOM model of the system.
The whole system includes 5200 atoms. Into the high layer we put the active site
residues, the place where the substrate is going to be cleaved, and the terminal part of the
peptide that comes to close the macrocycle. In total 109 atoms were considered (Fig. 25).
Small system, QM
109 atoms
Big system, MM
5200 atoms
E(ONIOM) = E(MM, big) – E(MM, small) + E(QM, small)
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After the full optimization of the system, detailed examination of the system was
done. The modelled and optimized structure shows appropriate position of the active site
residues and the substrate (Fig. 26). Thus, Ser783 is in a geometrically beneficial position
to the substrate to start a nucleophilic attack of the carbonyl. The distance between the
atoms is 3.72 Å. His618 is close and in good orientation to proceed with the next step of
the catalytic mechanism (the distance is 1.82 Å). And, finally, Asp548 is close enough to
His618 with the distance of 1.94 Å.
Fig. 26 – The representation of substrate in the active site of the enzyme after the optimisation.
After this, the system is prepared for the study of the catalytic mechanism using
QM/MM method.
6. PROSPECTIVE FOR THE FUTURE
During this project the modelling of the system of enzyme and correct substrate
was done with the help of computational technics in order to use this system in the study
of catalytic mechanism with the atomistic level of theory. The study of the catalytic
mechanism can be done in three steps: nucleophilic attack of Ser of the carbonyl atom,
proton transfer from Ser to His, and proton transfer from His to Asp. These three steps are
followed by cleavage of the four stop signalling residues, and approaching of the N-termini
to the cleaved part to close and form a macrocycle of patellamide.
3.72
Ser783
1.82
1.94
His618
Asp548
Substrate
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III. IDENTIFYING PROTEIN STRUCTURE WITH
INFRARED SPECTROSCOPY
1. INTRODUCTION AND MOTIVATION
Two-dimensional infrared spectroscopy (2DIR) [86, 87], applied to the amide-I
vibrations (C=O stretch) of proteins, has been shown to offer a powerful tool for the study
of protein conformational change. Since the very first experimental demonstration of the
technique, numerous proteins have been studied experimentally with the technique [88,
89] and ways of distinguishing typical secondary structures as α-helices [90], β-sheets
[89], and 310-helices [91] have been developed. Only within the last few years theoretical
methods capable of detailed simulation of two-dimensional spectra of full proteins from
molecular dynamics trajectories have become available [92, 93]. Still these new methods
have not been widely tested on available experimental data. The goal of the present
project is to apply these new simulation methods to proteins for which the experimental
data are readily available (as myoglobin, lysozyme, ribonuclease A, and concanavalin A
[89]) in order to benchmark the calculation methods.
In this project, molecular dynamics simulations of the proteins of interest have
been performed using the GROMACS MD-package [94]. From these trajectories the
needed vibrational frequencies and transition dipoles have been extracted [95 – 97] using
three different schemes. This information has then been processed with the newest
version of the NISE program [92, 98] to calculate the 2DIR spectra of the different
proteins. The spectra have been compared with experimental spectra, obtained from the
Tokmakoff group at the University of Chicago [99], and analysed on the base of visual
observation, overlap and RMSD between experimental and simulated spectra.
2. 2D INFRARED SPECTROSCOPY OF PROTEINS
Two-dimensional infrared spectroscopy is a new approach in the study of protein
conformation and conformational dynamics that occur on picosecond to millisecond time
scales. As a vibrational spectroscopy, it examines the vibrations of chemical bonds and
how many vibrations of a molecule and its environment interact with one another.
However, macromolecules as proteins have so many degrees of freedom that FTIR
spectra are often considered ambiguous therefore they display little variation for different
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proteins due to the broad and featureless line shape that arises from different structural
motifs. One can simplify the visualization of complex spectra consisting of many
overlapped peaks by spreading a vibrational spectrum over second independent
frequency dimension to reveal two-dimensional line shapes and cross-peaks. Cross-
peaks are hallmark of multidimensional spectroscopy. They are a measure of the coupling
between molecular vibrations and thus contain information on the molecular structure.
Infrared absorption is a result of the interaction between an electromagnetic field
and the oscillating molecular dipole moment. In one-dimensional experiment there is one
independent time or frequency variable. For example, in a frequency-domain experiment,
one measures the change of light intensity through a sample as a function of the
frequency of a monochromatic field. In the case of two-dimensional spectroscopy, one
measures the change to the absorption spectrum induced by excitation at an independent
frequency. This also can be performed in the frequency-domain as a double resonance
experiment with independent excitation and detection beams. Fourier transform methods
are commonly applied in one or both dimensions of the 2D spectrum. Following the initial
short pulse excitation (Fig. 27), subsequent pulses can interact with the sample
polarization in order to generate a nonlinear polarization. Since multiple pulses can
excite/de-excite the sample multiple times, the final nonlinear polarization radiates light
carrying frequencies with new information about the molecular potential not present in
linear absorption spectrum.
Fig. 27 – Pulse sequences for FTIR and 2D IR spectroscopy [100].
Structural information is extracted from the position and intensities of the peaks,
whereas dynamics are extracted from the peak shapes, more specifically, the ellipticity of
the peaks as well as the change in ellipticity with waiting time. Exciting a molecule during
the first time delay and probing it during the third time delay, the observation of the signal
of the molecule would be at a point in the spectrum connected with the frequency it had
during the first delay along the ω1 axis, and the frequency it had during the third time delay
along the ω3 axis. If the frequency didn’t change during waiting time then it would be
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observed a diagonal elongation, referred to as inhomogeneous broadening. If on the other
hand the dynamics is very fast compared to the waiting time all molecules will have lost
their memory of their initial frequency after the waiting time and the peak will be round, or
elongated antidiagonal, referred to as homogeneous broadening.
In the very first experimental demonstration of the technic 2D IR was applied to the
amide-I vibrations that are known for secondary structure sensitivity. We review 2D IR
spectroscopy of the amide I protein backbone vibration.
Modelling of Amide I Spectroscopy
Amide group vibrations of the protein backbone are of great attention in protein IR
spectroscopy because they are native to all proteins and the absorption is strong. The
most studied amide I modes (1600 – 1700 cm-1) that include primarily C=O stretching are
delocalized over the entire protein backbone, and are sensitive to the global structure of
the protein. Amide I vibrations are largely isolated from the other protein vibrations and
can be described as linear combinations of local amide I vibrations at each peptide unit.
With the exception of proline the side chain vibrations do not interact strongly with the
amide I vibration.
The sensitivity of amide I vibrations to the secondary structure of the protein
resulting from strong coupling between amide I oscillator of different residues and the
coupling depends on the structure of the protein. The peaks for α-helices and unstructured
regions are observed at 1640–1660 cm-1 and 1640–1650 cm-1, respectively. While for β-
sheets two peaks are observed, a strong absorption band near 1630–1640 cm-1 and a
weaker band at high frequencies (>1680 cm-1) [100, 101].
Model for amide I spectroscopy
On a computational level a theoretical model for amide I spectroscopy must
account for local and global effects.
Local effects come from the influence of an oscillator’s (local modes are often
referred to as oscillators or sites) local electrostatic environment on its vibrational
frequency (also known as site energy). It is the influence of local interactions on bond
strength within the amide unit. For example, hydrogen bonds between water molecules
and oxygen of the amide unit stabilizes the C=O bond, lowering its vibrational frequency
(and causing a red-shift of the corresponding amide I absorption peak). Therefore, this
site can be associated with the local hydrogen bonding configuration in which the peptide
resides. The correlation of local structure and vibrational frequency can be expressed in
terms of electrostatic variables (potential, field, gradient, etc.), which is the basis for most
of the site energy maps. Although the details of these methods vary, all seek to predict IR
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spectroscopic features based on the local electrostatic environment of each oscillator in a
given structure.
Global effects come from the delocalization of amide excitations due to its site-to-
site coupling. For description of the vibrational frequencies of individual sites local
electrostatic effects would be sufficient. But interactions between neighbouring residues
induce delocalization of vibrational modes across multiple residues, thus given rise to a
more complicated picture. For this reason, beyond electrostatics, the central feature of
most theoretical descriptions of amide I vibrations is the concept of the vibrational exciton
– a delocalized excited state produced by the interaction of many individual sites. These
vibrational excitons observed in amide I spectra can be compared to a network of
oscillators – or sites – coupled together into a single system. Vibrational coupling between
individual amide units in a protein causes excitation of any given amide vibration to induce
vibrations in adjacent units. This delocalization of vibrational motion over a system
depends on the number of sites, the site-to-site coupling strength, and the variation of site
energies.
3. PROCEDURE
A mixed quantum-classical approach is used in the methods to model FTIR and
2DIR spectra. The principal assumption is an adiabatic separation of the amide I
vibrational motions and the dynamics of the protein. It is stated that essentially all large
amplitude protein motions, such as conformational fluctuations, can be treated classically
via static protein structures or MD simulations, while the higher frequency vibrations, such
as amide I which are examined by the infrared radiation, must be treated quantum-
mechanically. The interaction between the amide I vibrations and protein structure is
handled with the mapping procedures.
The amide I Hamiltonian that describes the interactions between N sites includes
doubly excited states. The exciton states are described as eigenstates of the following
exciton Hamiltonian (equation 1):
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Here, n and mnJ represent the site energies and coupling constants between
singly-excited states. The second set of terms represent doubly-excited states, in which a
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single oscillator is excited twice (m=n), or two different oscillators are each excited (m≠n).
∆ is the anharmonicity value (~16 cm-1 for amide I) due to the anharmonicity of harmonic
oscillator. This value is particularly important for 2D spectroscopy. This value is the
difference in the absorption frequency for the fundamental transition (0 → 1) compared to
with its overtone (1 → 2). For a perfectly harmonic system (with ∆=0), the 2D IR signal
vanishes due to interference between the fundamental and overtone transitions. The
coupling between the one- and two-quantum states is neglected, so that the states are
separated into zero, one-, and two-quantum subspaces. The resulting block-diagonal
amide I Hamiltonian is illustrated graphically in Fig. 28, in which site energies occur along
the diagonal and site-to-site couplings appear off-diagonal within the one- and two-exciton
blocks. The eigenstates of the system are obtained by numerically diagonalizing the
resulting matrix, providing absorption frequency values, dipole moments, and oscillator
strengths. Usually, a harmonic approximation is assumed to obtain the two-exciton
coupling constants ,mn jkJ from the one-exciton energies n and coupling constants mnJ .
Fig. 28 – Schematic representation of the excitonic Hamiltonian matrix and energy levels for a 2-oscillator system [100].
To calculate those values, it is necessary to know the site energies and coupling
constants for each state. These parameters can be obtained from molecular structures
(for example, from MD simulations). To extract them from the MD simulation, a variety of
parametrized maps is used, without the need for electronic structure calculations. The
maps correlate the local structure (site energies are dependent on the local structure) and
electrostatic environment of the amide bond with the frequencies of the associated
vibrational modes in order to greatly reduce computational expense of calculating site
frequencies.
The maps are constructed from electronic structure calculations on N-methyl
acetamide (NMA), a model system for the peptide bond monomer. The maps assume a
linear correlation between the frequency and electrostatic parameters. For the study in the
present project were selected three following maps: Jansen, Skinner and Tokmakoff
maps.
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Jansen map was parameterized through DFT calculations on NMA – a model of
peptide bond – in point charge environment [95].
Skinner map [102] is an empirical map, constructed on the base of NMA in
different solvents.
Tokmakoff map is an empirical map, constructed on the base of Alanine and
Glycine dipeptides [103].
The second set of parameters – the site-to-site coupling constants mnJ was first
modelled using the transition dipole coupling (TDC) model [104, 105]. TDC model treats
through-space coupling by treating each oscillator as a simple dipole vector which
interacts with adjacent dipoles through a coupling factor. An improvement model of the
TDC is the transition charge coupling (TCC) [95, 106] model in which a transition charge
is assigned to each atom of the amide bond, and interaction energy is calculated between
each atom. In the present study the TCC model for the couplings between amide I
vibrations of different sites was used.
After amide-I Hamiltonian is constructed, it’s diagonalized and the eigenstates and
eigenvectors are used to calculate transition frequencies and dipole moments. These
values are then used for simulating spectra.
The procedure for simulating linear absorption and 2D IR spectra can be
summarised in the following scheme (Fig. 29). The Hamiltonian is constructed by
combining a MD trajectory with a mapping procedure to obtain the amide I frequencies
and couplings. After that, scheme of solving the Shrödinger equation is applied to obtain
the spectra.
Fig. 29 – A diagram for the procedure of simulating linear absorption and 2D IR spectra
MD simulation
Map
(Amide I) Hamiltonian
Spectra
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4. COMPUTATIONAL DETAILS
Protein selection
Myoglobin                                       Lysozyme
Ribonuclease A                                Concanavalin A
Fig. 30 – The structures (in ribbon representation) of the four proteins under the study.
The set of proteins used in the study (Fig. 30) was selected to include a variety
of structures ranging from mainly α-helical protein to mainly β-sheet protein. There
were chosen four proteins for which experimental data had already been obtained by
Tokmakoff group [99]. Myoglobin (Mb, 153 residues, PDB ID 5MBN; 0% β-sheet, 74%
α-helix structure) has no β-sheets. Lysozyme (Lys, 129 residues, PDB ID 1AKI; 6% β-
sheet, 31% α-helix structure) has a small three-stranded β-sheet region.
Ribonuclease A (RNse A, 124 residues, PDB ID 1FS3; 32% β-sheet, 18% α-helix
structure) has two domains that vary from two- to four-stranded regions. And
Concanavalin A (Con A, 237 residues, PDB ID 1NLS; 46% β-sheet, 0% α-helix
structure is the most extended system, with two relatively flat six-stranded AP β-
sheets.
MD simulations
MD simulations were performed with GROMACS-4.6.5 [94]. Except for myoglobin,
for all the proteins the implemented improved side-chain torsion potentials for the Amber
ff99SB protein force field – Amber 99SB-ILDN [107] was used. Due to the presence of
parameters for heme group of myoglobin, MD simulation of this protein was performed
using GROMOS 54a7 [108], where the parameters are implemented. The protein
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crystallographic structures were downloaded from the Protein Data Base. Missing protons
were filled in, and the protein structures were solvated in explicit water solvent
SPC/E water [109], and chlorine or sodium ions were added to keep the system neutral.
Finally, the systems were relaxed (to be sure that no steric clashes or inappropriate
geometry take place) by energy minimization with 50000 steps.
Equilibration was conducted in two phases: 100-ps NVT equilibration (constant
Number of particles, Volume, and Temperature) that stabilized the temperature of the
system, and 100-ps NPT equilibration (Number of particles, Pressure, and Temperature
are all constant) that stabilizes the pressure (and thus also the density) of the system.
Upon completion of the two equilibration phases, the system was well-equilibrated
at the desired temperature and pressure. Afterwards a 1-ns MD simulation with 2 ps time
step was performed. The structures and trajectories were stored every 20 fs, giving a total
of 50 000 stored snapshots.
Constructing of the amide-I Hamiltonian
For every snapshot of MD trajectory, the amide-I Hamiltonian was constructed,
using AmideImaps v. 1.0.0, to calculate transition dipole moments and site frequencies.
For frequency calculation, three different schemes for electrostatic maps were used:
Jansen map, Skinner map and Tokmakoff map.
Long range couplings, i.e. couplings between non-nearest neighbours, were
treated with TCC. Nearest neighbour Couplings, i.e. between nearest neighbours, were
treated with GLDP scheme, by the Torii and Tasumi map [111], based on the Hartree-
Fock ab-initio calculations of the glycin dipeptide (GLDP) for different Ramachandran
angles.
Spectral simulation (NISE v. 2A)
The linear absorption and 2D IR spectra were calculated using the NISE method
[98, 110], which is based on numerically solving the time-dependent Schrödinger equation
for the amide I Hamiltonian.
In the spectral simulation, the side-chain carbonyl vibrations were neglected
(aspartic acid, glutamic acid, asparagine, and glutamine units). The frequency of this
vibration is in the same range as that of the backbone carbonyls, but no reliable model for
the solvent dependence of its frequency exists.
FCUP
Computational Chemistry Studies on Biological Systems
47
5. RESULTS, ANALYSIS AND DISCUSSION
5.1 Obtained linear spectra
Experimental FTIR spectra are shown in Fig. 31 [99]. Qualitatively, absorption
spectra associated with primarily α-helical proteins myoglobin and lysozyme are
characterized by a single band centred near 1650 cm-1 with an approximate diagonal
width of 50 cm-1, while proteins composed of primarily β-sheet show two peaks centred
near 1620-1640 and 1680 cm-1, respectively, resulting from vibrations whose main
transition dipoles lie perpendicular and parallel to the β-strands respectively.
Fig. 31 – Experimental FTIR spectra of the proteins.
The FTIR spectra show that, going from exclusively α-helix system myoglobin to
exclusively β-sheet system Con A, the peak amide-I transition frequency red-shifts from
1650 cm-1 and the absorption lines change their shape from symmetric to more decline-
shaped, and the peaks are becoming broader. This trend is expected with increasing β-
sheet content. Nevertheless, it is difficult to correlate the spectral profiles observed in
FTIR spectra with different structural elements present in this series of four proteins. In the
FTIR spectra, the two-peak structure indicating the presence of a β-sheet is hardly
evident. Only a weak shoulder is observed for Con A and RNse A, while no such shoulder
is present for myoglobin and lysozyme.
Theoretical linear absorption spectra using different maps are shown in the
Fig. 32. For clear visual comparison, the peak positions of the predicted spectra were
moved to the peak positions of experimental spectra. The shifts for each protein and each
map are presented in the Table 7. Excluding shift peak positions of myoglobin, for which
another force filed was used for MD simulations, there are some dependencies. Thus,
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Jansen scheme regularly overestimates frequencies for about 11 cm-1. Skinner and
Tokmakoff schemes underestimate frequencies, and the underestimation values is less
regular, for about 15 and 13cm-1 for Skinner and Tokmakoff maps, respectively. These
blue- and red-shifting frequencies should be done while applying corresponding map.
Fig. 32 – Predicted FTIR spectra for the proteins simulated using Jansen, Skinner and Tokmakoff maps.
Simulated spectra are shifted to the peak position of experimental spectra.
Mb Lys RNse A Con A
Jansen -3.8 -7.4 -12.1 -12.2
Skinner 21.9 19.9 11.4 12.7
Tokmakoff 23.5 10.9 18.4 10.2
Table 7 – Shift of the peak positions.
Looking onto spectra one can notice that generally Tokmakoff map gives narrower
spectra in comparison with the experimental spectra. As well for the β-sheet structures
RNse A and Con A there are multiple peaks. These can be a result of narrower
distribution of site frequencies. The analyses of the average site frequency distribution
(Table 8) showed that for Tokmakoff map the deviation from the average frequency is the
smallest.
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Mb Lys RNse A Con A
Jansen av. frequency (cm-1) 1665.6 1670.1 1671.5 1671.0
av. deviation (cm-1) 17.7 19.1 21.4 22.9
Skinner av. frequency (cm-1) 1638.8 1639.4 1643.5 1642.9
av. deviation (cm-1) 18.8 23.0 26.1 26.0
Tokmakoff av. frequency (cm-1) 1660.6 1667.5 1662.8 1661.8
av. deviation (cm-1) 17.7 19.6 20.1 19.9
Table 8 – Frequency site distribution of the protein.
To measure the difference between values predicted by models and the values
actually observed in the experiment the root-mean-square deviation (RMSD) was used,
Equation 2.
2(y y )exp theorRMSD   (2)
Analysing the values of RMSD presented below in the Table 9, it is clear that the
best values are observed for Skinner map, and the worst for Tokmakoff map.
Mb Lys RNse A Con A
Jansen 2.023 2.911 1.696 2.832
Skinner 1.479 2.490 1.550 1.629
Tokmakoff 3.234 3.123 3.346 2.939
Table 9 – RMSD analysis between theoretical and experimental spectra.
To measure the similarity of the spectra quantitatively, the value of overlapping S
(Equation 3) between each simulated spectra and experimental one was used, as well as
overlapping between experimental spectra of proteins.
2 2(y y )
exp theor
exp theor
y yS   (3)
The results of overlapping are presented in the diagram below (Fig. 33). For
estimation of these values two limits were used, presented by blue and red horizontal
lines. These limits can be used to exclude inconsistent results. Thus, the lowest value
0.9449 is a value of overlapping between the two most different structures in this subset of
proteins revealed in the experiment; therefore under this limit theoretical models are not
able to differentiate between the two proteins. The highest value 0.9886 is a value of
overlapping between the two most similar structures; therefore it is likely a lot to have
overlapping between theoretical and experimental spectra close or higher to this limit. As
can be seen from this diagram the best values are obtained for the Skinner map, where
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the overlapping in most cases is close to the upper limit and for Con A it’s even higher.
The Jansen map, except for Lysozyme, as well showed high overlapping. Whereas, the
worst values are obtained for the Tokmakoff map.
Fig. 33 – Diagram of overlapping between simulated FTIR spectra and experimental ones for each protein. Upper limit is the
highest overlapping between experimental spectra of proteins. Lower limit is the lowest overlapping between experimental
spectra of proteins.
5.2. Obtained 2DIR spectra
Experimentally obtained 2D IR spectra [99] are given in the Fig. 34. The 2D IR
spectra show considerably more features about the structure in comparison with linear
absorption and allow the β-sheet features not apparent in the FTIR spectra to be
discriminated.
In proteins, interference effects between diagonal and cross-peaks, combined with
contributions from disordered regions and other secondary structures, lead to a “Z”-
shaped contour profile in the 2D IR amide I correlation spectrum that is characteristic
indicator of the presence of AP β-sheet secondary structure.
0.89
0.9
0.91
0.92
0.93
0.94
0.95
0.96
0.97
0.98
0.99
1
Myoglobin Lysozyme RNse A Con A
Jansen
Skinner
Tokmakoff
FCUP
Computational Chemistry Studies on Biological Systems
51
Fig. 34 – Experimental 2DIR spectra for the proteins.
In the Fig. 35 are presented theoretical 2D IR spectra together with experimental
spectra (on the top of the figure). For Con A all maps reproduce cross-peak, related to the
β-sheet secondary structure. It can be observed as broadening of the peak.
All the peaks and shoulders, appeared in the linear absorption spectra, are
highlited in the 2D spectra. Thus, there are clear peaks in the Tokmakoff map for β-sheet
structures of RNse A and Con A. There are present diagonal peaks in the spectra of
myoglobin, corresponding to the shoulders in the linear absorption spectra.
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Myoglobin Lysozyme RNse A Concanavalin A
Fig. 35 – Experimental and simulated spectra for the proteins.
In the Table 10 are presented the values of RMSD. The values are bigger than the
ones for linear spectra, but the tendency is the same – Skinner map gives slightly better
results.
Mb Lys RNse A Con A
Jansen 25.803 28.482 28.441 23.800
Skinner 26.754 27.140 22.146 10.515
Tokmakoff 30.757 27.580 27.729 12.214
Table 10 – RMSD analysis between theoretical and experimental 2D IR spectra.
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The same as for linear spectra, overlapping analysis was done. The overlapping
between experimental and theoretical spectra was done for each protein and each map
without moving peak positions. The results of overlapping are presented in the diagram
below (Fig. 36). From the diagram it is clearly seen that the Skinner map gives slightly
higher values.
Fig. 36 – Diagram of overlapping between simulated and experimental 2D IR spectra.
In general, Tokmakoff map is worst in reproducing the shapes of the experimental
spectra, while Jansen and Skinner maps are considerably close to each other. But the
values of overlapping doesn’t show the worst results, probably due to the contribution of
small additional peaks to the overlapping. Better results showed Skinner map,
reproducing better the shap of the peaks, and having the smalles RMSD values and
highest values of overlapping.
6. CONCLUSIONS AND OUTLOOK
The results show that 2D IR spectroscopy is more sensitive to structural
differences between proteins than traditional infrared spectroscopy. Infrared spectroscopy
is thus an appealing probe because it is intrinsic to all proteins and is sensitive to
conformation structure. Moreover, as a method with intrinsic time resolution in the
picosecond range, infrared methods can be applied to study the fast kinetics of protein
conformational changes accompanying protein folding.
Although there are models for simulating 2D spectra of proteins, there are still
difficulties that can be faced. One of them is absorption of side-chain vibrations in the
amide I region. Despite the fact that several side-chain groups absorb in the amide I
spectral region, these moieties are usually neglected for spectral calculations, while the
spectra of real peptides will contain contributions from side-chain vibrations in the amide I
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region. An accurately parameterized site energy map for these groups would be of interest
for many applications, particularly since their vibrations are expected to be largely
localized, making them potentially useful as probes of local structure. Benchmarking of
such parameterized site energy maps is very useful since it gives an opportunity to
estimate the given method using particular set of parameters applying for particular
systems. Together with estimating errors in calculations it helps identifying opportunities
for improvement the method. This is useful for developing new mappings.
In this project the calculation of 2D spectra was done, using one set of parameters.
In principle, one may vary and adjust the parameters to his own need. For example, by
testing on other systems, changing force field for MD simulation, comparing coupling
models.
FCUP
Computational Chemistry Studies on Biological Systems
55
REFERENCES
[1] R.M. Carey, AT1 Receptors, Angiotensin Receptor Blockade, and Clinical
Hypertensive Disease; In Renin Angiotensin System and Cardiovascular Disease
Contemporary Cardiology; W.C. DeMello, E.D. Frohlich, Eds.; Humana Press, 2009:59.
[2] R.M. Carey, Pathophysiology of Primary Hypertension; In Handbook of
Physiology: Microcirculation; R.F. Tuma, W.N. Duran, K. Ley, Eds.; Elsevier: Amsterdam,
2008, 2:794.
[3] J. Drews, Drug Discovery: A Historical Perspective; Science, 2000, 287:1960.
[4] X. Jeunemaitre, A.P. Gimenez-Roqueplo, J. Célérier, P. Corvol,
Angiotensinogen variants and human hypertension; Curr. Hypertens. Rep., 1999, 1:31.
[5] A. Cappelli, G.L. Mohr, A. Gallelli, M. Rizzo, M. Anzini, S. Vomero, L. Mennuni,
F. Ferrari, F. Makovec, M.C. Menziani, P.G. De Benedetti, G. Giorgi, Design, Synthesis,
Structural Studies, Biological Evaluation, and Computational Simulations of Novel Potent
AT1 Angiotensin II Receptor Antagonists Based on the 4-Phenylquinoline Structure;
J. Med. Chem., 2004, 47:2574.
[6] B. Scheiper, H. Matter, H. Steinhagen, U. Stilz, Z. Bocskei, V. Fleury,
G. McCort, Discovery and optimization of a new class of potent and non-chiral indole-3-
carboxamide-based renin inhibitors; Bioorg. Med. Chem. Lett., 2010, 20:6268.
[7] C. Jensen, P. Herold and H.R. Brunner, Aliskiren: the first renin inhibitor for
clinical treatment; Nat. Rev. Drug Discov., 2008, 7:399.
[8] G.K. Aulakh, R.K. Sodhi and M. Singh, An update on non-peptide angiotensin
receptor antagonists and related RAAS modulators; Life Sciencies, 2007, 81:615.
[9] F. Messerli, M.A. Weber, H.R. Brunner, Angiotensin II receptor inhibition: A new
therapeutic principle; Arch. Intern. Med., 1996, 156:1957.
[10] T.L. Goodfriend, M.E. Elliott, K.J. Catt, Angiotensin receptors and their
antagonists; N. Engl. J. Med., 1996, 334:1649.
[11] M. Caffrey, Membrane Protein Crystallization; J. Struct. Biol., 2003, 142:108.
[12] E. Krieger, S.B. Nabuurs, and G. Vriend, Homology Modeling; In Structural
Bioinformatics, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2003, 44.
[13] K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox,
I. Le Trong, D.C. Teller, T. Okada, R.E. Stenkamp, M. Yamamoto, M. Miyano, Crystal
structure of rhodopsin: A G protein-coupled receptor; Science, 2000, 289:739.
[14] V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G. Rasmussen, F.S. Thian,
T.S. Kobilka, H.J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka, R.C. Stevens, High-resolution
crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor;
Science, 2007, 318(5854): 1258.
FCUP
Computational Chemistry Studies on Biological Systems
56
[15] D. Wacker, G. Fenalti, M.A. Brown, V. Katritch, R. Abagyan, V. Cherezov,
R.C. Stevens, Conserved binding mode of human beta2 adrenergic receptor inverse
agonists and antagonist revealed by X-ray crystallography; J. Am. Chem. Soc., 2010,
132(33):11443.
[16] B. Wu, E.Y. Chien, C.D. Mol, G. Fenalti, W. Liu, V. Katritch, R. Abagyan,
A. Brooun, P. Wells, F.C. Bi, D.J. Hamel, P. Kuhn, T.M. Handel, V. Cherezov,
R.C. Stevens, Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic
peptide antagonists; Science, 2010, 330(6007):1066.
[17] M. Burnier, Angiotensin II type 1 receptor blockers; Circulation, 2001, 103:904.
[18] R.K. Turker, I.H. Page, F.M. Bumpus, Antagonists of angiotensin II; In: Hand-
book of Experimental Pharmacology, I.H. Pagi, F.M. Bumpus, Eds.; Angiotensin, Springer
Verlag, New York, 1974, 37:162.
[19] D.H.P. Streeten, G.H. Anderson, J.M. Freiberg, T.G. Dalakos, Use of an
angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic”
hypertension; N. Engl. J. Med., 1975, 292:657.
[20] Y. Furakawa, S. Kishimoto, K. Nishikawa, Hypotensive imidazole derivatives
and hypotensive imidazole-5-acetic acid derivatives; U.S. Patents 4,340,598 and
4,355,040. Osaka, Japan, 1982.
[21] E.K. Jackson, Renin and angiotensin; In: L. Brunton, J. Lazo, K. Parker, et al.,
Eds., Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 11th Ed. New
York: McGraw-Hill, 2006:789.
[22] P.B. Timmermans, P.C. Wong, A.T. Chiu, W.F. Herblin, P. Benfield,
D.J. Carini, R.J. Lee, R.R. Wexler, J.A. Saye, R.D. Smith, Angiotensin II receptors and
angiotensin II receptor antagonists; Pharmacol. Rev., 1993, 45:205.
[23] P. Buhlmayer, P. Furet, L. Criscione, M. de Gasparo, S. Whitebread,
T. Schmidlin, R. Lattmann, J. Wood, Valsartan, a potent, orally active angiotensin II
antagonist developed from the structurally new amino acid series; Bioorganic & Medicinal
Chemistry Letters, 1994, 4:29.
[24] B. Christophe, R. Libon, C. Cazaubon, D. Nisato, A. Manning, P. Chatelain,
Effects of irbesartan (SR 47436/BMS-186295) on angiotensin IIinduced pressor
responses in pithed rat: potential mechanisms of action; European Journal of
Pharmacology, 1995, 281:161.
[25] Y. Shibouta, Y. Inada, M. Ojima, T. Wada, M. Noda, T. Sanada, K. Kubo,
K. Nishikawa, Pharmacological profile of a highly potent and long-acting angiotensin II
receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-
benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-
FCUP
Computational Chemistry Studies on Biological Systems
57
(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-
1H-benzimidazole-7-carboxylate (TCV-116); Journal of Pharmacology and Experimental
Therapeutics, 1993, 266:114.
[26] K. Nishikawa, Y. Inada, Y. Shibouta, T. Wada, M. Ojima, K. Kubo, T. Naka,
Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor
antagonist, TCV-116; Blood Pressure Suppl., 1994, 5:7.
[27] M. Noda, Y. Shibouta, Y. Inada, M. Ojima, T. Wada, T. Sanada, K. Kubo,
Y. Kohara, T. Naka, K. Nishikawa, Inhibition of rabbit aortic angiotensin II (AII) receptor by
CV-11974, a new nonpeptide AII antagonist; Biochemical Pharmacology, 1993, 46:311.
[28] T.L. Blundell, S. Bedarkar, E. Rinderknecht, R.E. Humble, Insulin-like growth
factor: a model for tertiary structure accounting for immunoreactivity and receptor binding;
Proc Natl Acad Sci., 1978, 75:180.
[29] I.T. Weber, Evaluation of homology modeling of HIV protease; Proteins, 1990,
7(2):172.
[30] C.B. Anfinsen, Principles that govern the folding of protein chains, Science,
1973, 181:223.
[31] M.S. Johnson, N. Srinivasan, R. Sowdhamini, T.L. Blundell, Knowledge-based
protein Modelling; Crit Rev Biochem Mol Biol., 1994, 29(1):1.
[32] J.M. Chandonia, S.E. Brenner, Implications of structural genomics target
selection strategies: Pfam5000, whole genome, and random approaches; Proteins, 2005,
58:166.
[33] D. Vitkup, E. Melamud, J. Moult, C. Sander, Completeness in structural
genomics; Nat Struct Biol., 2001, 8:559.
[34] Modeller: https://salilab.org/modeller/about_modeller.html
[35] A. Sali, T.L. Blundell, Comparative protein modelling by satisfaction of spatial
restraints; J. Mol. Biol., 1993, 234:779.
[36] B. John, A. Sali, Comparative protein structure Modelling by iterative
alignment, model building and model assessment; Nucleic Acids Res, 2003, 31(14):3982.
[37] J. Wang, P. Cieplak, P. Kollman, How Well Does a Restrained Electrostatic
Potential (RESP) Model Perform in Calculating Conformational Energies of Organic and
Biological Molecules? Journal of Computational Chemistry, 2000, 21(12):1049.
[38] M. Takeda-Shitaka, D. Takaya, C. Chiba, H. Tanaka, H. Umeyama, Protein
structure prediction in structure based drug design; Curr Med Chem, 2004, 11:551.
[39] K. Joo, J. Lee, J Lee, Methods for accurate homology modeling by global
optimization; Methods Mol Biol., 2012, 857:175.
[40] E. Shakhnovich, Protein folding thermodynamics and dynamics: Where
physics, chemistry, and biology meet; Chem. Rev., 2006, 106:1559.
FCUP
Computational Chemistry Studies on Biological Systems
58
[41] C.L. Brooks, M. Karplus, B.M. Pettitt, Proteins: A theoretical perspective of
dynamics, structure, and thermodynamics; Wiley, New York, 1988:xiii.
[42] S. Tanaka, H.A. Scheraga, Medium- and long-range interaction parameters
between amino acids for predicting three-dimensional structures of proteins;
Macromolecules, 1976, 9:945.
[43] M.Y. Shen, A. Sali, Statistical potential for assessment and prediction of
protein structures; Protein Sci., 2006, 15(11):2507.
[44] F. Melo, R. Sanchez, A. Sali, Statistical potentials for fold assessment; Protein
Science, 2002, 11:430.
[45] R. Henderson, J.M. Baldwin, T.A. Ceska, F. Zemlin, E. Beckmann,
K.H. Downing, Model for the structure of bacteriorhodopsin based on high-resolution
electron cryo-microscopy; J Mol Biol, 1990, 213:899.
[46] M.P. Joseph, B. Maigret, J.C. Bonnafous, J. Marie, H.A. Scheraga, A
computer modeling postulated mechanism for angiotensin II receptor activation; J. Protein
Chem., 1995, 14:381.
[47] Y. Yamano, K. Ohyama, M. Kikyo, T. Sano, Y. Nakagomi, Y. Inoue,
N. Nakamura, I. Morishima, D.F. Guo, T. Hamakubo, T. Inagami, Mutagenesis and the
molecular modeling of the rat angiotensin II receptor (AT1); J. Biol. Chem., 1995,
270:14024.
[48] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig,
I.N. Shindyalov, P.E. Bourne, The Protein Data Bank; Nucleic Acids Research, 2000,
28(1):235.
[49] D.C. Teller, T. Okada, C.A. Behnke, K. Palczewski, R.E. Stenkamp, Advances
in Determination of a High-Resolution Three-Dimensional Structure of Rhodopsin, a
Model of G-Protein-Coupled Receptors (GPCRs); Biochemistry, 2001, 40:7761.
[50] J. Li, P.C. Edwards, M. Burghammer, C. Villa, G.F. Schertler, Structure of
bovine rhodopsin in a trigonal crystal form; J Mol Biol., 2004, 343(5):1409.
[51] T. Okada, Y. Fujiyoshi, M. Silow, J. Navarro, E.M. Landau, Y. Shichida,
Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography;
Proc. Natl. Acad. Sci. USA, 2002, 99:5982.
[52] T. Okada, M. Sugihara, A.N. Bondar, M. Elstner, P. Entel, V. Buss, The retinal
conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure;
J. Mol. Biol., 2004, 342:571.
[53] H. Wu, D. Wacker, V. Katritch, M. Mileni, G.W. Han, E. Vardy, W. Liu,
A.A. Thompson, X.-P. Huang, F.I. Carroll, S.W. Mascarella, R.B. Westkaemper,
P.D. Mosier, B.L. Roth, V. Cherezov, R.C. Stevens, Structure of the human kappa opioid
receptor in complex with JDTic; Nature, 2012, 485(7398):327.
FCUP
Computational Chemistry Studies on Biological Systems
59
[54] SwissProt Database: http://www.uniprot.org/
[55] ClustalW2: http://www.ebi.ac.uk/Tools/msa/clustalw2/
[56] J.A. Ballesteros, H. Weinstein, Integrated methods for the construction of
three dimensional models and computational probing of structure function relations in
G protein-coupled receptors; Methods Neurosci., 1995, 25:366.
[57] G.N. Ramachandran, C. Ramakrishnan, V. Sasisekharan, Stereochemistry of
Polypeptide Chain Configurations; J Mol Biol, 1963, 7:95.
[58] A.L. Morris, M.W. MacArthur, E.G. Hutchinson, J.M. Thornton, Stereochemical
quality of protein structure coordinates; Proteins, 1992, 12:345.
[59] Amber: http://ambermd.org/
[60] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell,
A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor
flexibility; J Comput Chem., 2009, 30(16):2785
[61] N.M.F.S.A. Cerqueira, J. Ribeiro, P.A. Fernandes, M.J. Ramos, vsLab—An
implementation for virtual high-throughput screening using AutoDock and VMD;
Int. J. Quantum Chem., 2011, 111:1208
[62] F.L.P. Fierens, P.M.L. Vanderheyden, Z. Gáborik, T. Le Minh, J.P. De Backer,
L. Hunyady, A. Ijzerman, G. Vauquelin. Lys 199 mutation of the human angiotensin type 1
receptor differentially affects the binding of surmountable and insurmountable non-peptide
antagonists; J. Renin-Angiotensin-Aldosterone System, 2000, 1:283.
[63] P. Zoumpoulakis, T. Mavromoustakos, Seeking the active site of the AT1
receptor for computational docking studies; Drug Design Reviews-Online, 2005, 2:537.
[64] L. Hunyady, H. Ji, G. Jagadeesh, M. Zhang, Z. Gaborik, B. Mihalik, K.J. Catt,
Dependence of AT(1) Angiotensin receptor function on adjacent asparagine residues in
the 7th transmembrane helix; Molecular pharmacology, 1998, 54(2):427.
[65] H. Ji, W. Zheng, Y. Zhang, K.J. Catt, K. Sandberg, Genetic transfer of a
nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor;
PNAS, 1995, 92(20):9240.
[66] T. Takezako, C. Gogonea, Y. Saad, K. Noda, S.S. Karnik, “Network leaning”
as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by
non-peptide antagonists; J. Biol. Chem., 2004, 279:15248.
[67] L. Yan, B.J. Holleran, P. Lavigne, E. Escher, G. Guillemette, R. Leduc,
Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by
cysteine-scanning mutagenesis; J. Biol. Chem., 2010, 285:2284.
[68] K. Noda, Y. Saad, A. Kinoshita, T.P. Boyle, R.M. Graham, A. Husain,
S.S. Karnik, Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to
the same subsite by different mechanisms; J Biol Chem, 1995, 270:2284.
FCUP
Computational Chemistry Studies on Biological Systems
60
[69] H.T. Schambye, S.A. Hjorth, J. Weinstock, T.W. Schwartz, Interaction
between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16)
of the angiotensin type 1 receptor; Mol Pharmacol, 1995, 47(3):425.
[70] H.M. Han, S.I. Shimuta, C.A. Kanashiro, L. Oliveira, S.W. Han, A.C. Paiva,
Residues Val254, His256, and Phe259 of the angiotensin II AT1 receptor are not involved
in ligand binding but participate in signal transduction; Mol Endocrinol, 1998, 12(6):810.
[71] S.S. Martin, B.J. Holleran, E. Escher, G. Guillemette, R. Leduc, Activation of
the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain:
Analysis by the substituted cysteine accessibility method; Mol. Pharmacol., 2007, 72:182.
[72] D. Fillion, J. Cabana, G. Guillemette, R. Leduc, P. Lavigne, E. Escher,
Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from
multiple chemoselective photoprobe contacts reveals a unique peptide binding mode;
J. Biol. Chem., 2013, 288:8187.
[73] ChemSpider: http://www.chemspider.com/
[74] Drug Bank: http://www.drugbank.ca/
[75] PubMed database: http://www.ncbi.nlm.nih.gov/pubmed
[76] ZINC database: http://zinc.docking.org/
[77] J. Koehnke, A. Bent, W.E. Houssen, D. Zollman, F. Morawitz, S. Shirran,
J. Vendome, A.F. Nneoyiegbe, L. Trembleau, C.H. Botting, M.C.M. Smith, M. Jaspars,
J.H. Naismith, The mechanism of patellamide macrocyclization revealed by the
characterization of the PatG macrocyclase domain; Nat Struct Mol Biol., 2012, 19(8):767.
[78] B.F. Milne, P.F. Long, A. Starcevic, D. Hranueli, M. Jaspars, Spontaneity in
the patellamide biosynthetic pathway; Org Biomol Chem., 2006, 4(4):631.
[79] D.F. Sesin, S.J. Gaskell, C.M. Ireland, The Chemistry of Lissoclinum Patella;
Bull. Soc. Chim. Belges, 1986, 95:853.
[80] E.W. Schmidt, J.T. Nelson, D.A. Rasko, S. Sudek, J.A. Eisen, M.G. Haygood,
J. Ravel, Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron
didemni, the cyanobacterial symbiont of Lissoclinum patella; Proc. Natl. Acad. Sci. USA,
2005, 102:7315.
[81] P.F. Long, W.C. Dunlap, C.N. Battershill, M. Jaspars, Shotgun cloning and
heterologous expression of the patellamide gene cluster as a strategy to achieving
sustained metabolite production; ChemBioChem, 2005, 6:1760.
[82] E.W. Schmidt, The hidden diversity of ribosomal peptide natural products;
BMC Biol., 2010, 8:83.
[83] W.E. Houssen, M. Jaspars, Azole-based cyclic peptides from the sea squirt
Lissoclinum patella: old scaffolds, new avenues; ChemBioChem, 2010, 11:1803.
FCUP
Computational Chemistry Studies on Biological Systems
61
[84] J.A. McIntosh, C.R. Robertson, V. Agarwal, S.K. Nair, G.W. Bulaj,
E.W. Schmidt, Circular logic: nonribosomal peptide-like macrocyclization with a ribosomal
peptide catalyst; J. Am. Chem. Soc., 2010, 132:15499.
[85] Gaussian: http://www.gaussian.com/g_prod/gv5.htm
[86] P. Hamm, M.H. Lim, R.M. Hochstrasser, Structure of the amide I band of
peptides measured by femtosecond nonlinear-infrared spectroscopy; J. Phys. Chem. B,
1998, 102:6123.
[87] P. Hamm, M.T. Zanni, Concepts and Methods of 2D Infrared Spectroscopy;
Cambridge University Press, Cambridge, 2011.
[88] Z. Ganim, K.C. Jones, A. Tokmakoff, Insulin dimer dissociation and unfolding
revealed by amide I two-dimensional infrared spectroscopy; Chem. Phys., 2010, 12:3579.
[89] N. Demirdöven, C.M. Cheatum, H.S. Chung, M. Khalil, J. Knoester,
A. Tokmakoff, Two-Dimensional Infrared Spectroscopy of Antiparallel β-Sheet Secondary
Structure; J. Am. Chem. Soc., 2004, 126:7981.
[90] S. Woutersen, P. Hamm, Time-resolved two-dimensional vibrational
spectroscopy of a short α-helix in water; J. Chem. Phys., 2001, 115:7737.
[91] H. Maekawa, C. Toniolo, A. Moretto, Q.B. Broxterman, N.-H. Ge, Different
spectral signatures of octapeptide 310- and α-helices revealed by two-dimensional infrared
spectroscopy; J. Phys. Chem. B, 2006, 110:5835.
[92] C. Liang, T.L.C. Jansen, An efficient N3-Scaling propagation scheme for
simulating two-dimensional infrared and visible spectra; J. Chem. Theory Comput., 2012,
8:706.
[93] C. Liang, M. Louhivuori, S.J. Marrink, T.L.C. Jansen, J. Knoester, Vibrational
spectra of a mechanosensitive channel; J. Phys. Chem. Lett., 2013, 4:448.
[94] E. Lindahl, B. Hess, D.v.d. Spoel, GROMACS 3.0: A package for molecular
simulation and trajectory analysis; J. Mol. Model., 2001, 7:306.
[95] T.L.C. Jansen, J. Knoester, A transferable electrostatic map for solvation
effects on amide I vibrations and its application to linear and two-dimensional
spectroscopy; J. Chem. Phys., 2006, 124:044502.
[96] T.L.C. Jansen, A.G. Dijkstra, T.M. Watson, J.D. Hirst, J. Knoester, Modeling
the amide I bands of small peptides; J. Chem. Phys., 2006, 125:044312.
[97] S. Roy, J. Lessing, G. Meisl, Z. Ganim, A. Tokmakoff, J. Knoester,
T.L.C. Jansen, Solvent and conformation dependence of amide I vibrations in peptides
and proteins containing proline; J. Chem. Phys., 2011, 135:234507.
[98] T.L.C. Jansen, J. Knoester, Nonadiabatic Effects in the two-dimensional
infrared spectra of peptides: Application to alanine dipeptide; J. Phys. Chem. B, 2006,
110:22910.
FCUP
Computational Chemistry Studies on Biological Systems
62
[99] C.R. Baiz, C.S. Peng, M.E. Reppert, K.C. Jones, A. Tokmakoff, Coherent two-
dimensional infrared spectroscopy: Quantitative analysis of protein secondary structure in
solution; Analyst, 2012, 137:1793.
[100] C.R. Baiz, M. Reppert, A. Tokmakoff, Introduction to Protein 2D IR
Spectroscopy. Ultrafast Infrared Vibrational Spectroscopy; Michael D. Fayer, Ed.; CRC
Press, 2013, 12.
[101] Z. Ganim, H.S. Chung, A.W. Smith, L.P. Deflores, K.C. Jones, A. Tokmakoff,
Amide I two-dimensional infrared spectroscopy of proteins; Accounts of chemical
research, 2008, 41(3):432.
[102] L. Wang, C.T. Middleton, M.T. Zanni, J.L. Skinner, Development and
validation of transferable amide I vibrational frequency maps for peptides;
J. Phys. Chem. B, 2011, 115(13):3713.
[103] M. Reppert, A. Tokmakoff, Electrostatic frequency shifts in amide I vibrational
spectra: direct parameterization against experiment; J. Chem. Phys., 2013, 138:134116.
[104] S. Krimm, J. Bandekar, Vibrational spectroscopy and conformation of
peptides, polypeptides, and proteins; Adv Protein Chem, 1986, 38:181.
[105] H. Torii, M. Tasumi, Model calculations on the amide-I infrared bands of
globular proteins; J. Chem. Phys, 1992, 96(5):3379.
[106] P. Hamm, S. Woutersen, Coupling of the amide I modes of the glycine
dipeptide; Bull. Chem. Soc. Jpn., 2002, 75:985.
[107] K. Lindorff-Larsen, S. Piana, K. Palmo, P. Maragakis, J.L. Klepeis, R.O. Dror,
D.E. Shaw, Improved side-chain torsion potentials for the Amber ff99SB protein force
field; Proteins, 2010, 78:1950.
[108] N. Schmid, A.P. Eichenberger, A. Choutko, S. Riniker, M. Winger, A.E. Mark,
W.F. van Gunsteren, Definition and testing of the GROMOS force-field versions 54A7 and
54B7; Eur Biophys J., 2011, 40(7):843.
[109] H.J.C. Berendsen, J.R. Grigera, T.P. Straatsma, The missing term in
effective pair potentials; J. Phys. Chem., 1987, 91:6269.
[110] T.L.C. Jansen, J. Knoester, Simulation of two-dimensional infrared spectra
by numerical integration of the Schrödinger equation. In International Conference of
Computational Methods in Sciences and Engineering, Recent Progress in Computational
Sciences and Engineering, Vol. 7. T. Simos, G. Maroulis, Eds.; Brill Academic Publishers,
Leiden, The Netherlands, China, Crete, Greece, 2006
[111] H. Torii, M. Tasumi, Ab initio molecular orbital study of the amide I vibrational
interactions between the peptide groups in di- and tripeptides and considerations on the
conformation of the extended helix; J. Raman Spec., 1998, 29(1):81.
FCUP
Computational Chemistry Studies on Biological Systems
63
APPENDIX
Theoretical spectra of proteins for each tested map
